Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

William B. Campbell PhD
Chair, Professor
Department of Pharmacology and Toxicology

OFFICE ADDRESS:
Medical Education Building
8701 Watertown Plank Rd
Milwaukee, WI 53226

EDUCATION:
1961 - 1965 Graduated from High School, Sulphur Springs, TX
1965 - 1966 East Texas State University, Commerce, TX
1966 - 1970 BS Pharmacy, University of Texas, College of Pharmacy, Austin
1970 - 1974 PhD Pharmacology, University of Texas Health Science Center (Southwestern Medical Center), Dallas, TX

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
1968 - 1970 Undergraduate Research, University of Texas College of Pharmacy, Austin, TX
1969 - 1970 Teaching Assistant, The University of Texas, College of Pharmacy, Austin, TX
1970 - 1974 Pre-doctoral Fellow in Pharmacology, The University of Texas Health Science Center, Dallas, TX
1970 - 1974 Graduate Research, University of Texas Health Science Center, Dallas, TX
1974 - 1975 Post-doctoral Fellow, Medical College of Wisconsin, Milwaukee, WI
1974 - 1976 Post-doctoral Training, Medical College of Wisconsin, Milwaukee, WI

FACULTY APPOINTMENTS:
1975 - 1976 Instructor of Pharmacology, Medical College of Wisconsin, Milwaukee, WI
1976 - 1981 Assistant Professor of Pharmacology, The University of Texas Health Science Center, Dallas, TX
1981 - 1990 Associate Professor of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, TX
1990 - 1992 Professor of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, TX
1992 - Present Professor and Chairman, Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI

SPECIALTY BOARDS AND CERTIFICATION:
Certificates
Issued By Issue DateExpiration
Registered Pharmacist
Texas
None
 

AWARDS AND HONORS:
1966 - Present Phi Etta Sigma Honor Society, East Texas State University, Commerce, TX
1968 - Present Phi Kappa Phi Honor Society, University of Texas, Austin, TX
1968 - Present Rho Chi Honor Society, University of Texas, Austin, TX
1970 - Present Merck Award for Chemistry & Pharmacy, University of Texas, Austin, TX
1970 - Present Graduated with Highest Honors, University of Texas, Austin, TX
1974 - Present Outstanding Student Research, Sigma Xi Graduate Student Forum, University of Texas Health Science Center, Dallas, TX
1980 - 1985 Research Career Development Award, National Institutes of Health
1999 - Present Lewis K. Dahl Memorial Lecture, American Heart Association Council for High Blood Pressure Research, 72nd Scientific Sessions, Atlanta, GA
2003 - Present Outstanding Mentor and Teaching Award, Medical College of Wisconsin
2006 - Present Recipient of the 2006 Novartis Award for Hypertension Research
2010 - Present Paul M. Vanhoutte Award in Vascular Pharmacology
2013 - Present PhRMA Foundation Award in Excellence in Pharmacology/Toxciology
2014 - Present Faculty Vitality Award - Sabbatical, Magdalen College, Oxford University, UK, Medical College of Wisconsin
2014 - Present Eminent Scholar - Department of Pharmacology & Toxicology, Medical College of Wisconsin
2015 - Present Florence J. Williams Endowed Chair of Pharmacology & Toxicology, Medical College of Wisconsin

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
American Federation for Clinical Research
American Society of Pharmacology and Experimental Therapeutics
The Endocrine Society
American Heart Association (Council for Basic Science Research)
American Society for the Advancement of Science
American Heart Association (Advisory Council for High Blood Pressure Research)

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:
Editorship
1990 - 1998 Journal of Lipid Research
1997 - 1999 Hypertension
1998 - 2005 Journal of Pharmacology and Experimental Therapeutics
2005 - Present Basic and Clinical Pharmacology and Toxicology
01/2007 Prostaglandins & Other Lipid Mediators
Editorial Board
1982 - 1987 Hypertension
1999 - Present Vascular Pharmacology
2000 - Present Hypertension
2006 Prostaglandins & Other Lipid Mediators
Journal Review
Journal of Biological Chemistry
Journal of Cardiovascular Pharmacology
Journal of Clinical Investigations
Journal of Lipid Research
Journal of Pharmacology and Experimental Therapeutics
Molecular Pharmacology
Proceedings of the National Academy of Science (USA)
Prostaglandins
Vascular Pharmacology
Hypertension
Endocrinology
Circulation Research
Circulation
Prostaglandins and Other Lipid Mediators
Biochimica Biophysica Acta
Basic and Clinical Pharmacology and Toxicology
Arteriosclerosis, Thrombosis and Vascular Biology
American Journal of Physiology
Biochemical Pharmacology

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
1979 National Institutes of Health, Ad Hoc Grant Reviewer
1983 Program Committee, American Heart Association, Council for High Blood Pressure Research
1983 National Institutes of Health, Ad Hoc Grant Reviewer
1984 - 1988 Member, National Institutes of Health Cardiovascular and Renal Study Section
1986 National Institutes of Health, Ad Hoc Grant Reviewer
1987 - 1988 Program Committee, American Heart Association, Council for High Blood Pressure Research
1988 Veterans Administration Merit Review Program, Ad Hoc Grant Reviewer
1988 - 1992 National Institutes of Health Reviewers Reserve
1990 National Institutes of Health, Ad Hoc Grant Reviewer
1992 - 1999 Publication Committee, American Heart Association, Council for High Blood Pressure Research
1992 - 1995 Program Committee, American Society for Pharmacology and Experimental Therapeutics
1994 Burroughs-Wellcome Foundation, Ad Hoc Grant Reviewer
1995 - 1996 Veterans Administration Merit Review Program, Ad Hoc Grant Reviewer
1996 - 1999 Chairman, Publications Committee, American Heart Association, Council for High Blood Pressure Research
1996 - 1999 Executive Committee, American Heart Association, Council for High Blood Pressure Research
1996 - 1999 Program Committee, American Heart Association, Council for High Blood Pressure Research
1997 National Institutes of Health, Ad Hoc Grant Reviewer
1998 - 2002 Councilor, Great Lakes Chapter, American Society for Pharmacology & Experimental Therapeutics
1998 - 2002 Scientific Committee, Workshop on Endothelium-Derived Hyperpolarizing Factor at Abbaye des Vaux de Cernay, France
1998 Burroughs-Wellcome Foundation, Ad Hoc Grant Reviewer
1999 National Institutes of Health, Ad Hoc Grant Reviewer
1999 American Heart Association, Council for High Blood Pressure Research Strategic Planning Retreat, New Orleans, LA
1999 - 2002 Chair, Program Committee, Division for Cardiovascular Pharmacology, American Society for Pharmacology and Experimental Therapeutics
1999 - 2000 National Heart Foundation of Australia, Ad Hoc Grant Review
1999 Veterans Administration Merit Review Program, Ad Hoc Grant Reviewer
2000 Burroughs-Wellcome Foundation, Ad Hoc Grant Reviewer
2002 - 2006 Member-at-Large Leadership Committee of the Council on High Blood Pressure Research
2002 - 2006 American Heart Association Scientific Publishing Committee
2004 National Heart Foundation of Australia, Ad Hoc Grant Review
2005 Scientific Committee, Mechanisms of Vasodilation and EDHF, Antwerp, Belgium
2006 - Present Scientific Organizing Committee, Winter Eicosanoid Conference, Baltimore, MD
2010 American Heart Association, Novartis Award Selection Committee
2011 American Heart Association, Council on the High Blood Pressure Research 2010-2011, Excellence Award for Hypertension Research Selection Committee


BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Pettinger WA, Campbell WB, Keeton K. Adrenergic component of renin release induced by vasodilating antihypertensive drugs in the rat. Circ Res. 1973 Jul;33(1):82-6.
2. Campbell WB, Brooks SN, Pettinger WA. Angiotensin II- and angiotensin 3-induced aldosterone release vivo in the rat. Science. 1974 May 31;184(4140):994-6.
3. Campbell WB, Sen S. Letter: Renin in the spontaneously hypertensive rat. Circ Res. 1974 Dec;35(6):961-3.
4. Pettinger WA, Tanaka K, Keeton K, Campbell WB, Brooks SN. Renin release, an artifact of anesthesia and its implications in rats. Proc Soc Exp Biol Med. 1975 Mar;148(3):625-30.
5. Campbell WB, Pettinger WA, Keeton K, Brooks SN. Vasodilating antihypertensive drug-induced aldosterone release--a study of endogenous angiotensin-mediated aldosterone release in the rat. J Pharmacol Exp Ther. 1975 Apr;193(1):166-75.
6. Campbell WB, Pettinger WA. Sodium chloride suppression of renin release in the unanesthetized rat. Endocrinology. 1975 Dec;97(6):1394-7.
7. Morris M, Campbell WB, Pettinger WA. Renin and hemodynamic changes via central adrenergic, cholinergic, and sodium receptor mechanisms in conscious rats. Proc Soc Exp Biol Med. 1976 Jan;151(1):101-4.
8. Pettinger WA, Keeton TK, Campbell WB, Harper DC. Evidence for a renal alpha-adrenergic receptor inhibiting renin release. Circ Res. 1976 May;38(5):338-46.
9. Keeton TK, Pettinger WA, Campbell WB. The effects of altered sodium balance and adrenergic blockade on renin release induced in rats by angiotensin antagonism. Circ Res. 1976 Jun;38(6):531-9.
10. Campbell WB, Pettinger WA. Organ specificity of angiotensin II and Des-aspartyl angiotensin II in the conscious rat. J Pharmacol Exp Ther. 1976 Aug;198(2):450-6.
11. Campbell WB, Itskovitz HD. Effect of histamine and antihistamines on renal hemodynamics and functions in the isolated perfused canine kidney. J Pharmacol Exp Ther. 1976 Sep;198(3):661-7.
12. Itskovitz HD, Campbell WB. Vasodilators, intrarenal distribution of blood flow, and renal function in isolated perfused canine kidneys. Proc Soc Exp Biol Med. 1976 Oct;153(1):161-5.
13. Campbell WB, Schmitz JM, Itskovitz HD. (Des-Asp1) angiotensin I: a study of its pressor and steroidogenic activities in conscious rats. Endocrinology. 1977 Jan;100(1):46-51.
14. Campbell WB, Schmitz JM, Itskovitz HD. The adrenal and vascular effects of angiotensin II and III in sodium depleted rats. Life Sci. 1977 Mar 01;20(5):803-9.
15. Campbell WB, Schmitz JM. Effect of alterations in dietary potassium on the pressor and steroidogenic effects of angiotensins II and III. Endocrinology. 1978 Dec;103(6):2098-104.
16. Gullner HG, Campbell WB, Pettinger WA. Effects of substance P on renin release and renal function in anesthetized dogs. Life Sci. 1979 Jan 15;24(3):237-45.
17. Campbell WB, Jackson EK. Modulation of adrenergic transmission by angiotensins in the perfused rat mesentery. Am J Physiol. 1979 Feb;236(2):H211-7.
18. Campbell WB, Schmitz JM. (7-Ile) angiotensin III: a relatively selective antagonist of angiotensin steroidogenesis. Eur J Pharmacol. 1979 Mar 01;54(3):209-16.
19. Campbell WB, Schmitz JM, Itskovitz HD. Effect of sodium depletion on the steroidogenic and pressor actions of angiotensin in the rat. Clin Sci (Lond). 1979 Apr;56(4):325-33.
20. Campbell WB, Ward PE. Renal metabolism of substance P in the dog. Life Sci. 1979 May 21;24(21):1995-2001.
21. Gullner HG, Campbell WB, Pettinger WA. Role of substance P in water homeostasis. Life Sci. 1979 Jun 18;24(25):2351-9.
22. Campbell WB, Graham RM, Jackson EK. Role of renal prostaglandins in sympathetically mediated renin relase in the rat. J Clin Invest. 1979 Aug;64(2):448-56. PMCID: PMC372139
23. Higashihara E, Stokes JB, Kokko JP, Campbell WB, DuBose TD Jr. Cortical and papillary micropuncture examination of chloride transport in segments of the rat kidney during inhibition of prostaglandin production. Possible role for prostaglandins in the chloruresis of acute volume expansion. J Clin Invest. 1979 Nov;64(5):1277-87. PMCID: PMC371274
24. Campbell WB, Jackson EK, Graham RM. Saralasin-induced renin release: its blockade by prostaglandin synthesis inhibitors in the conscious rat. Hypertension. 1979 Nov-Dec;1(6):637-42.
25. Campbell WB, Gomez-Sanchez CE, Adams BV, Schmitz JM, Itskovitz HD. Attenuation of angiotensin II- and III-induced aldosterone release by prostaglandin synthesis inhibitors. J Clin Invest. 1979 Dec;64(6):1552-7. PMCID: PMC371307
26. Campbell WB, Graham RM, Jackson EK, Loisel DP, Pettinger WA. Effect of indomethacin on hydralazine-induced renin and catecholamine release in the conscious rabbit. Br J Pharmacol. 1980;71(2):529-31. PMCID: PMC2044447
27. Jackson EK, Campbell WB. Inhibition of angiotensin II potentiation of sympathetic nerve activity by beta-adrenergic antagonists. Hypertension. 1980 Jan-Feb;2(1):90-6.
28. Campbell WB, Zimmer JA. Insulin-induced renin release: blockade by indomethacin in the rat. Clin Sci (Lond). 1980 May;58(5):415-8.
29. Keeton TK, Campbell WB. The pharmacologic alteration of renin release. Pharmacol Rev. 1980 Jun;32(2):81-227.
30. Campbell WB, Gomez-Sanchez CE, Adams BV. Role of prostaglandins in angiotensin-induced steriodogenesis absence of an effect by prostaglandin E2. Hypertension. 1980 Jul-Aug;2(4):471-6.
31. Brater DC, Beck JM, Adams BV, Campbell WB. Effects of indomethacin on furosemide-stimulated urinary PGE2 excretion in man. Eur J Pharmacol. 1980 Jul 25;65(2-3):213-9.
32. Campbell WB, Graham RM, Jackson EK. Inhibition of hydralazine-induced renin release by indomethacin in the rat. Arch Int Pharmacodyn Ther. 1980 Aug;246(2):315-23.
33. Jackson EK, Campbell WB. The in situ blood perfused rat mesentery; a model for assessing modulation of adrenergic neurotransmission. Eur J Pharmacol. 1980 Aug 29;66(2-3):217-24.
34. Campbell WB, Holland OB, Gomez-Sanchez CE, Graham RM, Pettinger WA, White AC. Plasma substance P levels in normotensive and hypertensive subjects. Clin Exp Hypertens. 1981;3(2):183-93.
35. Jackson EK, Campbell WB. A possible antihypertensive mechanism of propranolol: antagonism of angiotensin II enhancement of sympathetic nerve transmission through prostaglandins. Hypertension. 1981 Jan-Feb;3(1):23-33.
36. Johnson AR, Callahan KS, Tsai SC, Campbell WB. Prostacyclin and prostaglandin biosynthesis in human pulmonary endothelial cells. Bull Eur Physiopathol Respir. 1981;17(4):531-51.
37. Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson JT. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med. 1981 Mar 19;304(12):685-91.
38. Graham RM, Campbell WB. Speculative approaches in hypertension: concepts and drugs of the future. Fed Proc. 1981 Jun;40(8):2291-5.
39. Hirsh PD, Campbell WB, Willerson JT, Hillis LD. Prostaglandins and ischemic heart disease. Am J Med. 1981 Dec;71(6):1009-26.
40. Campbell WB, Johnson AR, Callahan KS, Graham RM. Anti-platelet activity of beta-adrenergic antagonists: inhibition of thromboxane synthesis and platelet aggregation in patients receiving long-term propranolol treatment. Lancet. 1981 Dec 19-26;2(8260-61):1382-4.
41. Henrich WL, Hamasaki Y, Said SI, Campbell WB, Cronin RE. Dissociation of systemic and renal effects in endotoxemia. Prostaglandin inhibition uncovers an important role of renal nerves. J Clin Invest. 1982 Mar;69(3):691-9. PMCID: PMC371027
42. Graham RM, Campbell WB, Jackson EK. Effects of short-term beta blockade on blood pressure, plasma thromboxane B2, and plasma and urinary prostaglandins E2 and F2 alpha in normal subjects. Clin Pharmacol Ther. 1982 Mar;31(3):324-9.
43. Hirsh PD, Firth BG, Campbell WB, Willerson JT, Hillis LD. Influence of blood sampling site and technique on thromboxane concentrations in patients with ischemic heart disease. Am Heart J. 1982 Aug;104(2 Pt 1):234-7.
44. Campbell WB, Holland OB, Adams BV, Gomez-Sanchez CE. Urinary excretion of prostaglandin E2, prostaglandin F2 alpha, and thromboxane B2 in normotensive and hypertensive subjects on varying sodium intakes. Hypertension. 1982 Sep-Oct;4(5):735-41.
45. Ojeda SR, Campbell WB. An increase in hypothalamic capacity to synthesize prostaglandin E2 precedes the first preovulatory surge of gonadotropins. Endocrinology. 1982 Oct;111(4):1031-7.
46. Alhenc-Gelas F, Tsai SJ, Callahan KS, Campbell WB, Johnson AR. Stimulation of prostaglandin formation by vasoactive mediators in cultured human endothelial cells. Prostaglandins. 1982 Nov;24(5):723-42.
47. Bush LR, Campbell WB, Tilton GD, Buja LM, Willerson JT. Effects of the selective thromboxane synthetase inhibitor, dazoxiben, on cyclic flow variations in stenosed canine coronary arteries. Trans Assoc Am Physicians. 1983;96:103-12.
48. Hillis LD, Hirsh PD, Campbell WB, Firth BG. Interactions of the arterial wall, plaque, and platelets in myocardial ischemia and infarction. Cardiovasc Clin. 1983;14(1):31-44.
49. Hirsh PD, Firth BG, Campbell WB, Dehmer GJ, Willerson JT, Hillis LD. Effects of provocation on transcardiac thromboxane in patients with coronary artery disease. Am J Cardiol. 1983 Mar 01;51(5):727-33.
50. Holland OB, von Kuhnert L, Campbell WB, Anderson RJ. Synergistic effect of captopril with hydrochlorothiazide for the treatment of low-renin hypertensive black patients. Hypertension. 1983 Mar-Apr;5(2):235-9.
51. Firth BG, Winniford MD, Campbell WB, Hillis LD. Hemodynamic effects of intravenous prostacyclin in stable angina pectoris. Am J Cardiol. 1983 Sep 01;52(5):439-43.
52. Henrich WL, Campbell WB. The systemic beta-adrenergic pathway to renin secretion: relationships with the renal prostaglandin system. Endocrinology. 1983 Dec;113(6):2247-54.
53. Bush LR, Campbell WB, Buja LM, Tilton GD, Willerson JT. Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries. Circulation. 1984 Jun;69(6):1161-70.
54. Henrich WL, Campbell WB. Relationship between PG and beta-adrenergic pathways to renin release in rat renal cortical slices. Am J Physiol. 1984 Sep;247(3 Pt 1):E343-8.
55. Nicod P, Winniford MD, Campbell WB, Rehr RB, Firth BG, Hillis LD. Alterations in coronary blood flow induced by cigarette smoking: lack of relation to plasma arginine vasopressin concentrations. Am J Cardiol. 1984 Sep 01;54(6):667-8.
56. Kaojarern S, Chennavasin P, Burdette A, Campbell WB, Brater DC. Dependence of urinary prostaglandin E2 excretion on urinary volume rather than solute handling or segmental nephron function in man. Clin Sci (Lond). 1984 Oct;67(4):413-20.
57. Nicod P, Rehr R, Winniford MD, Campbell WB, Firth BG, Hillis LD. Acute systemic and coronary hemodynamic and serologic responses to cigarette smoking in long-term smokers with atherosclerotic coronary artery disease. J Am Coll Cardiol. 1984 Nov;4(5):964-71.
58. Bush LR, Campbell WB, Kern K, Tilton GD, Apprill P, Ashton J, Schmitz J, Buja LM, Willerson JT. The effects of alpha 2-adrenergic and serotonergic receptor antagonists on cyclic blood flow alterations in stenosed canine coronary arteries. Circ Res. 1984 Nov;55(5):642-52.
59. Rehr RB, Jackson JA, Winniford MD, Campbell WB, Hillis LD. Mechanism of nitroglycerin-induced coronary dilatation: lack of relation to intracoronary thromboxane concentrations. Am J Cardiol. 1984 Nov 01;54(8):971-4.
60. Willerson JT, Campbell WB, Winniford MD, Schmitz J, Apprill P, Firth BG, Ashton J, Smitherman T, Bush L, Buja LM. Conversion from chronic to acute coronary artery disease: speculation regarding mechanisms. Am J Cardiol. 1984 Dec 01;54(10):1349-54.
61. Winniford MD, Jackson J, Malloy CR, Rehr RB, Campbell WB, Hillis LD. Does indomethacin attenuate the coronary vasodilatory effect of nitroglycerin? J Am Coll Cardiol. 1984 Dec;4(6):1114-7.
62. Johnson AR, Revtyak G, Campbell WB. Arachidonic acid metabolites and endothelial injury: studies with cultures of human endothelial cells. Fed Proc. 1985 Jan;44(1 Pt 1):19-24.
63. Brater DC, Anderson S, Baird B, Campbell WB. Effects of ibuprofen, naproxen, and sulindac on prostaglandins in men. Kidney Int. 1985 Jan;27(1):66-73.
64. Johnson AR, Revtyak GE, Ibe BO, Campbell WB. Endothelial cells metabolize but do not synthesize leukotrienes. Prog Clin Biol Res. 1985;199:185-96.
65. Callahan KS, Johnson AR, Campbell WB. Enhancement of the antiaggregatory activity of prostacyclin by propranolol in human platelets. Circulation. 1985 Jun;71(6):1237-46.
66. Campbell WB, Currie MG, Needleman P. Inhibition of aldosterone biosynthesis by atriopeptins in rat adrenal cells. Circ Res. 1985 Jul;57(1):113-8.
67. Campbell WB, Gomez-Sanchez CE. Absence of prostacyclin involvement in angiotensin-induced aldosterone secretion in rat adrenal cells. Endocrinology. 1985 Jul;117(1):279-86.
68. Apprill P, Schmitz JM, Campbell WB, Tilton G, Ashton J, Raheja S, Buja LM, Willerson JT. Cyclic blood flow variations induced by platelet-activating factor in stenosed canine coronary arteries despite inhibition of thromboxane synthetase, serotonin receptors, and alpha-adrenergic receptors. Circulation. 1985 Aug;72(2):397-405.
69. Schmitz JM, Apprill PG, Buja LM, Willerson JT, Campbell WB. Vascular prostaglandin and thromboxane production in a canine model of myocardial ischemia. Circ Res. 1985 Aug;57(2):223-31.
70. Campbell WB, Falck JR, Okita JR, Johnson AR, Callahan KS. Synthesis of dihomoprostaglandins from adrenic acid (7,10,13,16-docosatetraenoic acid) by human endothelial cells. Biochim Biophys Acta. 1985 Oct 23;837(1):67-76.
71. Henrich WL, Brater DC, Campbell WB. Renal hemodynamic effects of therapeutic plasma levels of sulindac sulfide during hemorrhage. Kidney Int. 1986 Feb;29(2):484-9.
72. Richards CF, Johnson AR, Campbell WB. Specific incorporation of 5-hydroxy-6,8,11,14-eicosatetraenoic acid into phosphatidylcholine in human endothelial cells. Biochim Biophys Acta. 1986 Feb 28;875(3):569-81.
73. Ashton JH, Benedict CR, Fitzgerald C, Raheja S, Taylor A, Campbell WB, Buja LM, Willerson JT. Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries. Circulation. 1986 Mar;73(3):572-8.
74. Campbell WB, Brady MT, Gomez-Sanchez CE. Effects of angiotensin, prostaglandin E2 and indomethacin on the early and late steps of aldosterone biosynthesis in isolated adrenal cells. J Steroid Biochem. 1986 Apr;24(4):865-70.
75. Henrich WL, Campbell WB. Importance of calcium in renal renin release. Am J Physiol. 1986 Jul;251(1 Pt 1):E98-103.
76. Lewis GD, Campbell WB, Johnson AR. Inhibition of prostaglandin synthesis by glucocorticoids in human endothelial cells. Endocrinology. 1986 Jul;119(1):62-9.
77. Henrich WL, Needleman P, Campbell WB. Effect of atriopeptin III on renin release in vitro. Life Sci. 1986 Sep 15;39(11):993-1001.
78. Ashton JH, Schmitz JM, Campbell WB, Ogletree ML, Raheja S, Taylor AL, Fitzgerald C, Buja LM, Willerson JT. Inhibition of cyclic flow variations in stenosed canine coronary arteries by thromboxane A2/prostaglandin H2 receptor antagonists. Circ Res. 1986 Nov;59(5):568-78.
79. Campbell WB, Ojeda SR. Measurement of prostaglandins by radioimmunoassay. Methods Enzymol. 1987;141:323-41.
80. Henrich WL, McAlister EA, Smith PB, Lipton J, Campbell WB. Direct inhibitory effect of atriopeptin III on renin release in primate kidney. Life Sci. 1987 Jul 20;41(3):259-64.
81. Ashton JH, Ogletree ML, Michel IM, Golino P, McNatt JM, Taylor AL, Raheja S, Schmitz J, Buja LM, Campbell WB. Cooperative mediation by serotonin S2 and thromboxane A2/prostaglandin H2 receptor activation of cyclic flow variations in dogs with severe coronary artery stenoses. Circulation. 1987 Oct;76(4):952-9.
82. Revtyak GE, Johnson AR, Campbell WB. Prostaglandin synthesis in bovine coronary endothelial cells: comparison with other commonly studied endothelial cells. Thromb Res. 1987 Dec 15;48(6):671-83.
83. Revtyak GE, Johnson AR, Campbell WB. Cultured bovine coronary arterial endothelial cells synthesize HETEs and prostacyclin. Am J Physiol. 1988 Jan;254(1 Pt 1):C8-19.
84. Ibe BO, Campbell WB. Synthesis and metabolism of leukotrienes by human endothelial cells: influence on prostacyclin release. Biochim Biophys Acta. 1988 Jun 15;960(3):309-21.
85. Revtyak GE, Hughes MJ, Johnson AR, Campbell WB. Histamine stimulation of prostaglandin and HETE synthesis in human endothelial cells. Am J Physiol. 1988 Aug;255(2 Pt 1):C214-25.
86. Henrich WL, McAllister EA, Smith PB, Campbell WB. Guanosine 3',5'-cyclic monophosphate as a mediator of inhibition of renin release. Am J Physiol. 1988 Sep;255(3 Pt 2):F474-8.
87. Dehmer GJ, Popma JJ, van den Berg EK, Eichhorn EJ, Prewitt JB, Campbell WB, Jennings L, Willerson JT, Schmitz JM. Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-3 fatty acids. N Engl J Med. 1988 Sep 22;319(12):733-40.
88. Pfister SL, Schmitz JM, Willerson JT, Campbell WB. Characterization of arachidonic acid metabolism in Watanabe heritable hyperlipidemic (WHHL) and New Zealand white (NZW) rabbit aortas. Prostaglandins. 1988 Oct;36(4):515-32.
89. Grover RF, Johnson RL Jr, McCullough RG, McCullough RE, Hofmeister SE, Campbell WB, Reynolds RC. Pulmonary hypertension and pulmonary vascular reactivity in beagles at high altitude. J Appl Physiol (1985). 1988 Dec;65(6):2632-40.
90. Golino P, Ashton JH, Buja LM, Rosolowsky M, Taylor AL, McNatt J, Campbell WB, Willerson JT. Local platelet activation causes vasoconstriction of large epicardial canine coronary arteries in vivo. Thromboxane A2 and serotonin are possible mediators. Circulation. 1989 Jan;79(1):154-66.
91. Pfister SL, Rosolowsky M, Schmitz JM, Clubb FJ Jr, Campbell WB. Eicosapentaenoic acid alters vascular reactivity and platelet adhesion in Watanabe heritable hyperlipidemic rabbits. Eur J Pharmacol. 1989 Feb 14;161(1):85-9.
92. Wines PA, Schmitz JM, Pfister SL, Clubb FJ Jr, Buja LM, Willerson JT, Campbell WB. Augmented vasoconstrictor responses to serotonin precede development of atherosclerosis in aorta of WHHL rabbit. Arteriosclerosis. 1989 Mar-Apr;9(2):195-202.
93. Ibe BO, Falck JR, Johnson AR, Campbell WB. Regulation of synthesis of prostacyclin and HETEs in human endothelial cells. Am J Physiol. 1989 Jun;256(6 Pt 1):C1168-75.
94. Clubb FJ Jr, Schmitz JM, Butler MM, Buja LM, Willerson JT, Campbell WB. Effect of dietary omega-3 fatty acid on serum lipids, platelet function, and atherosclerosis in Watanabe heritable hyperlipidemic rabbits. Arteriosclerosis. 1989 Jul-Aug;9(4):529-37.
95. Belardetti F, Campbell WB, Falck JR, Demontis G, Rosolowsky M. Products of heme-catalyzed transformation of the arachidonate derivative 12-HPETE open S-type K+ channels in Aplysia. Neuron. 1989 Oct;3(4):497-505.
96. Richards CF, Campbell WB. Incorporation of hydroxyeicosatetraenoic acids into cellular lipids of adrenal glomerulosa cells: inhibition of aldosterone release by 5-HETE. Prostaglandins. 1989 Nov;38(5):565-80.
97. Henrich WL, Falck JR, Campbell WB. Inhibition of renin release by 14,15-epoxyeicosatrienoic acid in renal cortical slices. Am J Physiol. 1990 Feb;258(2 Pt 1):E269-74.
98. Rosolowsky M, Falck JR, Willerson JT, Campbell WB. Synthesis of lipoxygenase and epoxygenase products of arachidonic acid by normal and stenosed canine coronary arteries. Circ Res. 1990 Mar;66(3):608-21.
99. Rosolowsky LJ, Campbell WB. Endothelin enhances adrenocorticotropin-stimulated aldosterone release from cultured bovine adrenal cells. Endocrinology. 1990 Apr;126(4):1860-6.
100. Butler MM, Griffey SM, Clubb FJ Jr, Gerrity LW, Campbell WB. The effect of euthanasia technique on vascular arachidonic acid metabolism and vascular and intestinal smooth muscle contractility. Lab Anim Sci. 1990 May;40(3):277-83.
101. Riedo FX, Munford RS, Campbell WB, Reisch JS, Chien KR, Gerard RD. Deacylated lipopolysaccharide inhibits plasminogen activator inhibitor-1, prostacyclin, and prostaglandin E2 induction by lipopolysaccharide but not by tumor necrosis factor-alpha. J Immunol. 1990 May 01;144(9):3506-12.
102. Revtyak GE, Buja LM, Chien KR, Campbell WB. Reduced arachidonate metabolism in ATP-depleted myocardial cells occurs early in cell injury. Am J Physiol. 1990 Aug;259(2 Pt 2):H582-91.
103. Campbell WB, Henrich WL. Endothelial factors in the regulation of renin release. Kidney Int. 1990 Oct;38(4):612-7.
104. Campbell WB, Hughes MJ, Osther K. A rapid screening test for HIV-1 antibodies: application to biological studies on human tissue. Life Sci. 1991;48(4):347-53.
105. Rosolowsky M, Falck JR, Campbell WB. Synthesis and biological activity of epoxyeicosatrienoic acids (EETs) by cultured bovine coronary artery endothelial cells. Adv Prostaglandin Thromboxane Leukot Res. 1991;21A:213-6.
106. Rosolowsky M, Pfister SL, Buja LM, Clubb FJ Jr, Campbell WB. Method of removal of aortic endothelium affects arachidonic acid metabolism and vascular reactivity. Eur J Pharmacol. 1991 Feb 14;193(3):293-300.
107. Moe O, Tejedor A, Campbell WB, Alpern RJ, Henrich WL. Effects of endothelin on in vitro renin secretion. Am J Physiol. 1991 Apr;260(4 Pt 1):E521-5.
108. Yao SK, Benedict CR, Rosolowsky M, McNatt J, Falinska B, Campbell WB, Buja LM, Willerson JT. Effect of aspirin on local prostaglandin production and serotonin accumulation in a canine model with coronary cyclic flow variations or thrombosis. J Mol Cell Cardiol. 1991 Apr;23(4):473-82.
109. Campbell WB, Brady MT, Rosolowsky LJ, Falck JR. Metabolism of arachidonic acid by rat adrenal glomerulosa cells: synthesis of hydroxyeicosatetraenoic acids and epoxyeicosatrienoic acids. Endocrinology. 1991 Apr;128(4):2183-94.
110. Pfister SL, Falck JR, Campbell WB. Enhanced synthesis of epoxyeicosatrienoic acids by cholesterol-fed rabbit aorta. Am J Physiol. 1991 Sep;261(3 Pt 2):H843-52.
111. Yao SK, Ober JC, McNatt J, Benedict CR, Rosolowsky M, Anderson HV, Cui K, Maffrand JP, Campbell WB, Buja LM. ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries. Circ Res. 1992 Jan;70(1):39-48.
112. Revtyak GE, Campbell WB. Inhibition of prostaglandin synthesis in human endothelial cells treated with metabolic inhibitors. Biochim Biophys Acta. 1992 Jan 24;1123(2):216-26.
113. Rosolowsky LJ, Campbell WB. Bradykinin stimulates aldosterone release from cultured bovine adrenocortical cells through bradykinin B2 receptors. Endocrinology. 1992 Apr;130(4):2067-75.
114. Henrich WL, Falck JR, Campbell WB. Inhibition of renin secretion from rat renal cortical slices by (R)-12-HETE. Am J Physiol. 1992 Oct;263(4 Pt 2):F665-70.
115. Pfister SL, Campbell WB. Arachidonic acid- and acetylcholine-induced relaxations of rabbit aorta. Hypertension. 1992 Nov;20(5):682-9.
116. Shaul PW, Campbell WB, Farrar MA, Magness RR. Oxygen modulates prostacyclin synthesis in ovine fetal pulmonary arteries by an effect on cyclooxygenase. J Clin Invest. 1992 Dec;90(6):2147-55. PMCID: PMC443365
117. Rosolowsky M, Campbell WB. Role of PGI2 and epoxyeicosatrienoic acids in relaxation of bovine coronary arteries to arachidonic acid. Am J Physiol. 1993 Feb;264(2 Pt 2):H327-35.
118. Buzzard CJ, Pfister SL, Campbell WB. Endothelium-dependent contractions in rabbit pulmonary artery are mediated by thromboxane A2. Circ Res. 1993 May;72(5):1023-34.
119. Rosolowsky LJ, Campbell WB. Endothelial cells stimulate aldosterone release from bovine adrenal zona glomerulosa cells. Am J Physiol. 1994 Jan;266(1 Pt 1):E107-17.
120. Harder DR, Gebremedhin D, Narayanan J, Jefcoat C, Falck JR, Campbell WB, Roman R. Formation and action of a P-450 4A metabolite of arachidonic acid in cat cerebral microvessels. Am J Physiol. 1994 May;266(5 Pt 2):H2098-107.
121. Buzzard CJ, Pfister SL, Halushka PV, Campbell WB. Decrease in vascular TxA2 receptors in a subgroup of rabbits unresponsive to a TxA2 mimetic. Am J Physiol. 1994 Jun;266(6 Pt 2):H2320-6.
122. Ambrosio G, Golino P, Pascucci I, Rosolowsky M, Campbell WB, DeClerck F, Tritto I, Chiariello M. Modulation of platelet function by reactive oxygen metabolites. Am J Physiol. 1994 Jul;267(1 Pt 2):H308-18.
123. North AJ, Brannon TS, Wells LB, Campbell WB, Shaul PW. Hypoxia stimulates prostacyclin synthesis in newborn pulmonary artery endothelium by increasing cyclooxygenase-1 protein. Circ Res. 1994 Jul;75(1):33-40.
124. Vasko MR, Campbell WB, Waite KJ. Prostaglandin E2 enhances bradykinin-stimulated release of neuropeptides from rat sensory neurons in culture. J Neurosci. 1994 Aug;14(8):4987-97. PMCID: PMC6577198
125. Hillard CJ, Edgemond WS, Campbell WB. Characterization of ligand binding to the cannabinoid receptor of rat brain membranes using a novel method: application to anandamide. J Neurochem. 1995 Feb;64(2):677-83.
126. Edgemond WS, Campbell WB, Hillard CJ. The binding of novel phenolic derivatives of anandamide to brain cannabinoid receptors. Prostaglandins Leukot Essent Fatty Acids. 1995 Feb-Mar;52(2-3):83-6.
127. Harder DR, Campbell WB, Roman RJ. Role of cytochrome P-450 enzymes and metabolites of arachidonic acid in the control of vascular tone. J Vasc Res. 1995 Mar-Apr;32(2):79-92.
128. Hillard CJ, Wilkison DM, Edgemond WS, Campbell WB. Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain. Biochim Biophys Acta. 1995 Aug 03;1257(3):249-56.
129. Pratt PF, Nithipatikom K, Campbell WB. Simultaneous determination of nitrate and nitrite in biological samples by multichannel flow injection analysis. Anal Biochem. 1995 Nov 01;231(2):383-6.
130. Hildebrandt E, Albanesi JP, Falck JR, Campbell WB. Regulation of calcium influx and catecholamine secretion in chromaffin cells by a cytochrome P450 metabolite of arachidonic acid. J Lipid Res. 1995 Dec;36(12):2599-608.
131. Pfister SL, Campbell WB. Role of endothelium-derived metabolites of arachidonic acid in enhanced pulmonary artery contractions in female rabbits. Hypertension. 1996 Jan;27(1):43-8.
132. Rosolowsky M, Campbell WB. Synthesis of hydroxyeicosatetraenoic (HETEs) and epoxyeicosatrienoic acids (EETs) by cultured bovine coronary artery endothelial cells. Biochim Biophys Acta. 1996 Jan 19;1299(2):267-77.
133. Nithipatikom K, Pratt PF, Campbell WB. Nitro-L-arginine inteferes with the cadmium reduction of nitrate/griess reaction method of measuring nitric oxide production. Eur J Clin Chem Clin Biochem. 1996 Feb;34(2):133-7.
134. Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res. 1996 Mar;78(3):415-23.
135. Pfister SL, Campbell WB. Reduced pulmonary artery vasoconstriction in methacholine in cholesterol-fed rabbits. Hypertension. 1996 Mar;27(3 Pt 2):804-10.
136. Pfister SL, Spitzbarth N, Edgemond W, Campbell WB. Vasorelaxation by an endothelium-derived metabolite of arachidonic acid. Am J Physiol. 1996 Mar;270(3 Pt 2):H1021-30.
137. Rosolowsky M, Falck JR, Campbell WB. Metabolism of arachidonic acid by canine polymorphonuclear leukocytes synthesis of lipoxygenase and omega-oxidized metabolites. Biochim Biophys Acta. 1996 Apr 19;1300(2):143-50.
138. Pratt PF, Rosolowsky M, Campbell WB. Mediators of arachidonic acid-induced relaxation of bovine coronary artery. Hypertension. 1996 Jul;28(1):76-82.
139. Kochar MS, Campbell WB. What's new in ... clinical pharmacology and therapeutics. Wis Med J. 1996 Sep;95(9):645-6.
140. Stein EA, Fuller SA, Edgemond WS, Campbell WB. Physiological and behavioural effects of the endogenous cannabinoid, arachidonylethanolamide (anandamide), in the rat. Br J Pharmacol. 1996 Sep;119(1):107-14. PMCID: PMC1915721
141. Pfister SL, Campbell WB. Contribution of arachidonic acid metabolites to reduced norepinephrine-induced contractions in hypercholesterolemic rabbit aortas. J Cardiovasc Pharmacol. 1996 Dec;28(6):784-91.
142. Hawi SR, Campbell WB, Kajdacsy-Balla A, Murphy R, Adar F, Nithipatikom K. Characterization of normal and malignant human hepatocytes by Raman microspectroscopy. Cancer Lett. 1996 Dec 20;110(1-2):35-40.
143. Pfister SL, Kotulock DA, Campbell WB. Vascular smooth muscle thromboxane A2 receptors mediate arachidonic acid-induced sudden death in rabbits. Hypertension. 1997 Jan;29(1 Pt 2):303-9.
144. Li PL, Zou AP, Campbell WB. Regulation of potassium channels in coronary arterial smooth muscle by endothelium-derived vasodilators. Hypertension. 1997 Jan;29(1 Pt 2):262-7.
145. Li P, Zou AP, Campbell WB. Metabolism and actions of ADP-riboses in coronary arterial smooth muscle. Adv Exp Med Biol. 1997;419:437-41.
146. Wohlfeil ER, Campbell WB. 25-Hydroxycholesterol enhances eicosanoid production in cultured bovine coronary artery endothelial cells by increasing prostaglandin G/H synthase-2. Biochim Biophys Acta. 1997 Mar 10;1345(1):109-20.
147. Nithipatikom K, Falck JR, Bhatt RK, Hanke CJ, Campbell WB. Determination of 14,15-epoxyeicosatrienoic acid and 14,15-dihydroxyeicosatrienoic acid by fluoroimmunoassay. Anal Biochem. 1997 Mar 15;246(2):253-9.
148. Li PL, Campbell WB. Epoxyeicosatrienoic acids activate K+ channels in coronary smooth muscle through a guanine nucleotide binding protein. Circ Res. 1997 Jun;80(6):877-84.
149. Hawi SR, Nithipatikom K, Wohlfeil ER, Adar F, Campbell WB. Raman microspectroscopy of intracellular cholesterol crystals in cultured bovine coronary artery endothelial cells. J Lipid Res. 1997 Aug;38(8):1591-7.
150. Hillard CJ, Edgemond WS, Jarrahian A, Campbell WB. Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J Neurochem. 1997 Aug;69(2):631-8.
151. Pratt PF, Hillard CJ, Edgemond WS, Campbell WB. N-arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor. Am J Physiol Heart Circ Physiol. 1998 Jan 01;274(1):H375-H381.
152. Li PL, Jin MW, Campbell WB. Effect of selective inhibition of soluble guanylyl cyclase on the K(Ca) channel activity in coronary artery smooth muscle. Hypertension. 1998 Jan;31(1 Pt 2):303-8.
153. Pratt PF, Falck JR, Reddy KM, Kurian JB, Campbell WB. 20-HETE relaxes bovine coronary arteries through the release of prostacyclin. Hypertension. 1998 Jan;31(1 Pt 2):237-41.
154. Pfister SL, Deinhart DD, Campbell WB. Methacholine-induced contraction of rabbit pulmonary artery: role of platelet-endothelial transcellular thromboxane synthesis. Hypertension. 1998 Jan;31(1 Pt 2):206-12.
155. Hillard CJ, Campbell WB. Biochemistry and pharmacology of arachidonylethanolamide, a putative endogenous cannabinoid. J Lipid Res. 1997 Dec;38(12):2383-98.
156. Pratt PF, Hillard CJ, Edgemond WS, Campbell WB. N-arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor. Am J Physiol. 1998 01;274(1):H375-81.
157. Csukas S, Hanke CJ, Rewolinski D, Campbell WB. Prostaglandin E2-induced aldosterone release is mediated by an EP2 receptor. Hypertension. 1998 Feb;31(2):575-81.
158. Hawi SR, Rochanakij S, Adar F, Campbell WB, Nithipatikom K. Detection of membrane-bound enzymes in cells using immunoassay and Raman microspectroscopy. Anal Biochem. 1998 Jun 01;259(2):212-7.
159. Edgemond WS, Greenberg MJ, McGinley PJ, Muthian S, Campbell WB, Hillard CJ. Synthesis and characterization of diazomethylarachidonyl ketone: an irreversible inhibitor of N-arachidonylethanolamine amidohydrolase. J Pharmacol Exp Ther. 1998 Jul;286(1):184-90.
160. Edgemond WS, Hillard CJ, Falck JR, Kearn CS, Campbell WB. Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): their affinities for cannabinoid receptors and pathways of inactivation. Mol Pharmacol. 1998 Jul;54(1):180-8.
161. Gebremedhin D, Harder DR, Pratt PF, Campbell WB. Bioassay of an endothelium-derived hyperpolarizing factor from bovine coronary arteries: role of a cytochrome P450 metabolite. J Vasc Res. 1998 Jul-Aug;35(4):274-84.
162. Li PL, Zou AP, Campbell WB. Regulation of K-channel activity by cyclic ADP-ribose and ADP-ribose in coronary arterial smooth muscle. Am J Physiol Heart Circ Physiol. 1998 Sep 01;275(3):H1002-H1010.
163. Li PL, Zou AP, Campbell WB. Regulation of KCa-channel activity by cyclic ADP-ribose and ADP-ribose in coronary arterial smooth muscle. Am J Physiol. 1998 09;275(3):H1002-10.
164. Hanke CJ, Drewett JG, Myers CR, Campbell WB. Nitric oxide inhibits aldosterone synthesis by a guanylyl cyclase-independent effect. Endocrinology. 1998 Oct;139(10):4053-60.
165. Stein EA, Fuller SA, Edgemond WS, Campbell WB. Selective effects of the endogenous cannabinoid arachidonylethanolamide (anandamide) on regional cerebral blood flow in the rat. Neuropsychopharmacology. 1998 Dec;19(6):481-91.
166. Pfister SL, Spitzbarth N, Nithipatikom K, Edgemond WS, Falck JR, Campbell WB. Identification of the 11,14,15- and 11,12, 15-trihydroxyeicosatrienoic acids as endothelium-derived relaxing factors of rabbit aorta. J Biol Chem. 1998 Nov 20;273(47):30879-87.
167. Campbell WB. Proceedings of the council for high blood pressure research, 1998 Hypertension. 1999 Jan;33(1 Pt 2):169.
168. Jacobs ER, Effros RM, Falck JR, Reddy KM, Campbell WB, Zhu D. Airway synthesis of 20-hydroxyeicosatetraenoic acid: metabolism by cyclooxygenase to a bronchodilator. Am J Physiol. 1999 02;276(2):L280-8.
169. Campbell WB, Harder DR. Endothelium-derived hyperpolarizing factors and vascular cytochrome P450 metabolites of arachidonic acid in the regulation of tone. Circ Res. 1999 Mar 05;84(4):484-8.
170. Hillard CJ, Manna S, Greenberg MJ, DiCamelli R, Ross RA, Stevenson LA, Murphy V, Pertwee RG, Campbell WB. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther. 1999 Jun;289(3):1427-33.
171. Gebremedhin D, Lange AR, Campbell WB, Hillard CJ, Harder DR. Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am J Physiol. 1999 06;276(6):H2085-93.
172. Li PL, Zhang DX, Zou AP, Campbell WB. Effect of ceramide on KCa channel activity and vascular tone in coronary arteries. Hypertension. 1999 Jun;33(6):1441-6.
173. Li PL, Chen CL, Bortell R, Campbell WB. 11,12-Epoxyeicosatrienoic acid stimulates endogenous mono-ADP-ribosylation in bovine coronary arterial smooth muscle. Circ Res. 1999 Aug 20;85(4):349-56.
174. Rosolowsky LJ, Hanke CJ, Campbell WB. Adrenal capillary endothelial cells stimulate aldosterone release through a protein that is distinct from endothelin. Endocrinology. 1999 Oct;140(10):4411-8.
175. Wohlfeil ER, Campbell WB. 25-hydroxycholesterol increases eicosanoids and alters morphology in cultured pulmonary artery smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol. 1999 Dec;19(12):2901-8.
176. Geiger J, Zou AP, Campbell WB, Li PL. Inhibition of cADP-ribose formation produces vasodilation in bovine coronary arteries. Hypertension. 2000 Jan;35(1 Pt 2):397-402.
177. Hanke CJ, O'Brien T, Pritchard KA Jr, Campbell WB. Inhibition of adrenal cell aldosterone synthesis by endogenous nitric oxide release. Hypertension. 2000 Jan;35(1 Pt 2):324-8.
178. Muthian S, Nithipatikom K, Campbell WB, Hillard CJ. Synthesis and characterization of a fluorescent substrate for the N-arachidonoylethanolamine (anandamide) transmembrane carrier. J Pharmacol Exp Ther. 2000 Apr;293(1):289-95.
179. Campbell WB. New role for epoxyeicosatrienoic acids as anti-inflammatory mediators. Trends Pharmacol Sci. 2000 Apr;21(4):125-7.
180. Jarrahian A, Manna S, Edgemond WS, Campbell WB, Hillard CJ. Structure-activity relationships among N-arachidonylethanolamine (Anandamide) head group analogues for the anandamide transporter. J Neurochem. 2000 Jun;74(6):2597-606.
181. Gebremedhin D, Lange AR, Lowry TF, Taheri MR, Birks EK, Hudetz AG, Narayanan J, Falck JR, Okamoto H, Roman RJ, Nithipatikom K, Campbell WB, Harder DR. Production of 20-HETE and its role in autoregulation of cerebral blood flow. Circ Res. 2000 Jul 07;87(1):60-5.
182. Ali I, Campbell WB, Sarna SK. Impaired activation of cytosolic phospolipase A(2) in inflamed canine colonic circular muscle. Gastroenterology. 2000 Jul;119(1):62-70.
183. Nithipatikom K, Pratt PF, Campbell WB. Determination of EETs using microbore liquid chromatography with fluorescence detection. Am J Physiol Heart Circ Physiol. 2000 Aug;279(2):H857-62.
184. Yu JZ, Zhang DX, Zou AP, Campbell WB, Li PL. Nitric oxide inhibits Ca(2+) mobilization through cADP-ribose signaling in coronary arterial smooth muscle cells. Am J Physiol Heart Circ Physiol. 2000 Sep;279(3):H873-81.
185. Hanke CJ, Campbell WB. Endothelial cell nitric oxide inhibits aldosterone synthesis in zona glomerulosa cells: modulation by oxygen. Am J Physiol Endocrinol Metab. 2000 Oct;279(4):E846-54.
186. Rady JJ, Campbell WB, Fujimoto JM. Antianalgesic action of nociceptin originating in the brain is mediated by spinal prostaglandin E(2) in mice. J Pharmacol Exp Ther. 2001 Jan;296(1):7-14.
187. Li PL, Tang WX, Valdivia HH, Zou AP, Campbell WB. cADP-ribose activates reconstituted ryanodine receptors from coronary arterial smooth muscle. Am J Physiol Heart Circ Physiol. 2001 Jan;280(1):H208-15.
188. Pratt PF, Li P, Hillard CJ, Kurian J, Campbell WB. Endothelium-independent, ouabain-sensitive relaxation of bovine coronary arteries by EETs. Am J Physiol Heart Circ Physiol. 2001 Mar;280(3):H1113-21.
189. Nithipatikom K, DiCamelli RF, Kohler S, Gumina RJ, Falck JR, Campbell WB, Gross GJ. Determination of cytochrome P450 metabolites of arachidonic acid in coronary venous plasma during ischemia and reperfusion in dogs. Anal Biochem. 2001 May 01;292(1):115-24.
190. Campbell WB, Harder DR. Prologue: EDHF--what is it? Am J Physiol Heart Circ Physiol. 2001 Jun;280(6):H2413-6.
191. Zhang DX, Fryer RM, Hsu AK, Zou AP, Gross GJ, Campbell WB, Li PL. Production and metabolism of ceramide in normal and ischemic-reperfused myocardium of rats. Basic Res Cardiol. 2001 May-Jun;96(3):267-74.
192. Campbell WB, Falck JR, Gauthier K. Role of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factor in bovine coronary arteries. Med Sci Monit. 2001 Jul-Aug;7(4):578-84.
193. Morgan ET, Ullrich V, Daiber A, Schmidt P, Takaya N, Shoun H, McGiff JC, Oyekan A, Hanke CJ, Campbell WB, Park CS, Kang JS, Yi HG, Cha YN, Mansuy D, Boucher JL. Cytochromes P450 and flavin monooxygenases--targets and sources of nitric oxide. Drug Metab Dispos. 2001 Nov;29(11):1366-76.
194. Li N, Zou AP, Ge ZD, Campbell WB, Li PL. Effect of nitric oxide on calcium-induced calcium release in coronary arterial smooth muscle. Gen Pharmacol. 2000 Jul;35(1):37-45.
195. Nithipatikom K, Grall AJ, Holmes BB, Harder DR, Falck JR, Campbell WB. Liquid chromatographic-electrospray ionization-mass spectrometric analysis of cytochrome P450 metabolites of arachidonic acid. Anal Biochem. 2001 Nov 15;298(2):327-36.
196. Zhang DX, Chen YF, Campbell WB, Zou AP, Gross GJ, Li PL. Characteristics and superoxide-induced activation of reconstituted myocardial mitochondrial ATP-sensitive potassium channels. Circ Res. 2001 Dec 07;89(12):1177-83.
197. Campbell WB, Gauthier KM. What is new in endothelium-derived hyperpolarizing factors? Curr Opin Nephrol Hypertens. 2002 Mar;11(2):177-83.
198. Tang WX, Chen YF, Zou AP, Campbell WB, Li PL. Role of FKBP12.6 in cADPR-induced activation of reconstituted ryanodine receptors from arterial smooth muscle. Am J Physiol Heart Circ Physiol. 2002 Apr;282(4):H1304-10.
199. Li PL, Zhang DX, Ge ZD, Campbell WB. Role of ADP-ribose in 11,12-EET-induced activation of K(Ca) channels in coronary arterial smooth muscle cells. Am J Physiol Heart Circ Physiol. 2002 Apr;282(4):H1229-36.
200. Campbell WB, Deeter C, Gauthier KM, Ingraham RH, Falck JR, Li PL. 14,15-Dihydroxyeicosatrienoic acid relaxes bovine coronary arteries by activation of K(Ca) channels. Am J Physiol Heart Circ Physiol. 2002 May;282(5):H1656-64.
201. Gauthier KM, Deeter C, Krishna UM, Reddy YK, Bondlela M, Falck JR, Campbell WB. 14,15-Epoxyeicosa-5(Z)-enoic acid: a selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries. Circ Res. 2002 May 17;90(9):1028-36.
202. Pratt PF, Rosolowsky M, Campbell WB. Effects of epoxyeicosatrienoic acids on polymorphonuclear leukocyte function. Life Sci. 2002 Apr 21;70(21):2521-33.
203. Yi FX, Zhang AY, Campbell WB, Zou AP, Van Breemen C, Li PL. Simultaneous in situ monitoring of intracellular Ca2+ and NO in endothelium of coronary arteries. Am J Physiol Heart Circ Physiol. 2002 Dec;283(6):H2725-32.
204. Falck JR, Krishna UM, Reddy YK, Kumar PS, Reddy KM, Hittner SB, Deeter C, Sharma KK, Gauthier KM, Campbell WB. Comparison of vasodilatory properties of 14,15-EET analogs: structural requirements for dilation. Am J Physiol Heart Circ Physiol. 2003 Jan;284(1):H337-49.
205. Pfister SL, Hughes MJ, Rosolowsky M, Campbell WB. Role of contaminating platelets in thromboxane synthesis in primary cultures of human umbilical vein endothelial cells. Prostaglandins Other Lipid Mediat. 2002 Sep;70(1-2):39-49.
206. Nithipatikom K, Laabs ND, Isbell MA, Campbell WB. Liquid chromatographic-mass spectrometric determination of cyclooxygenase metabolites of arachidonic acid in cultured cells. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Feb 25;785(1):135-45.
207. Archer SL, Gragasin FS, Wu X, Wang S, McMurtry S, Kim DH, Platonov M, Koshal A, Hashimoto K, Campbell WB, Falck JR, Michelakis ED. Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11,12-epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BK(Ca) channels. Circulation. 2003 Feb 11;107(5):769-76.
208. Ge ZD, Zhang DX, Chen YF, Yi FX, Zou AP, Campbell WB, Li PL. Cyclic ADP-ribose contributes to contraction and Ca2+ release by M1 muscarinic receptor activation in coronary arterial smooth muscle. J Vasc Res. 2003 Jan-Feb;40(1):28-36.
209. Nithipatikom K, Borscheid CL, Kajdacsy-Balla A, Kaul S, Lindholm PF, Pytynia KB, Campbell WB. Determination of cyclooxygenase and arachidonic acid metabolites in invasive human prostate cancer cells. Adv Exp Med Biol. 2002;507:269-74.
210. Sasaki DM, Yuan Y, Gikas K, Reddy M, Falck JR, Nithipatikom K, Campbell WB, Callewaert DM. Development of enzyme immunoassays for 5,6-, 8,9-, 11,12-, and 14,15- EETs and the corresponding DHETs. Adv Exp Med Biol. 2002;507:531-6.
211. Zhu D, Medhora M, Campbell WB, Spitzbarth N, Baker JE, Jacobs ER. Chronic hypoxia activates lung 15-lipoxygenase, which catalyzes production of 15-HETE and enhances constriction in neonatal rabbit pulmonary arteries. Circ Res. 2003 May 16;92(9):992-1000.
212. Skidgel RA, Alhenc-Gelas F, Campbell WB. Prologue: kinins and related systems. New life for old discoveries. Am J Physiol Heart Circ Physiol. 2003 Jun;284(6):H1886-91.
213. Pfister SL, Spitzbarth N, Nithipatikom K, Falck JR, Campbell WB. Metabolism of 12-hydroperoxyeicosatetraenoic acid to vasodilatory trioxilin C3 by rabbit aorta. Biochim Biophys Acta. 2003 Jun 20;1622(1):6-13.
214. Patel S, Wohlfeil ER, Rademacher DJ, Carrier EJ, Perry LJ, Kundu A, Falck JR, Nithipatikom K, Campbell WB, Hillard CJ. The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol. 2003 Jul;139(5):1005-13. PMCID: PMC1573928
215. Campbell WB, Spitzbarth N, Gauthier KM, Pfister SL. 11,12,15-Trihydroxyeicosatrienoic acid mediates ACh-induced relaxations in rabbit aorta. Am J Physiol Heart Circ Physiol. 2003 Dec;285(6):H2648-56.
216. Tang X, Spitzbarth N, Kuhn H, Chaitidis P, Campbell WB. Interleukin-13 upregulates vasodilatory 15-lipoxygenase eicosanoids in rabbit aorta. Arterioscler Thromb Vasc Biol. 2003 Oct 01;23(10):1768-74.
217. Gauthier KM, Jagadeesh SG, Falck JR, Campbell WB. 14,15-epoxyeicosa-5(Z)-enoic-mSI: a 14,15- and 5,6-EET antagonist in bovine coronary arteries. Hypertension. 2003 Oct;42(4):555-61.
218. Nithipatikom K, McCoy MJ, Hawi SR, Nakamoto K, Adar F, Campbell WB. Characterization and application of Raman labels for confocal Raman microspectroscopic detection of cellular proteins in single cells. Anal Biochem. 2003 Nov 15;322(2):198-207.
219. Kaduce TL, Fang X, Harmon SD, Oltman CL, Dellsperger KC, Teesch LM, Gopal VR, Falck JR, Campbell WB, Weintraub NL, Spector AA. 20-hydroxyeicosatetraenoic acid (20-HETE) metabolism in coronary endothelial cells. J Biol Chem. 2004 Jan 23;279(4):2648-56.
220. Pfister SL, Spitzbarth N, Zeldin DC, Lafite P, Mansuy D, Campbell WB. Rabbit aorta converts 15-HPETE to trihydroxyeicosatrienoic acids: potential role of cytochrome P450. Arch Biochem Biophys. 2003 Dec 01;420(1):142-52.
221. Gauthier KM, Spitzbarth N, Edwards EM, Campbell WB. Apamin-sensitive K+ currents mediate arachidonic acid-induced relaxations of rabbit aorta. Hypertension. 2004 Feb;43(2):413-9.
222. Krötz F, Riexinger T, Buerkle MA, Nithipatikom K, Gloe T, Sohn HY, Campbell WB, Pohl U. Membrane-potential-dependent inhibition of platelet adhesion to endothelial cells by epoxyeicosatrienoic acids. Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):595-600.
223. Goodfriend TL, Ball DL, Egan BM, Campbell WB, Nithipatikom K. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension. 2004 Feb;43(2):358-63.
224. Zhang DX, Gauthier KM, Campbell WB. Characterization of vasoconstrictor responses in small bovine adrenal cortical arteries in vitro. Endocrinology. 2004 Apr;145(4):1571-8.
225. Rademacher DJ, Kearn CS, Carrier EJ, Patel S, Delgado MA, Barkmeier A, Klick DE, Breese NM, Pfister SL, Nithipatikom K, Campbell WB, Hillard CJ. Production of hydroxyeicosatetraenoic acids and prostaglandins by a novel rat microglial cell line. J Neuroimmunol. 2004 Apr;149(1-2):130-41.
226. Gauthier KM, Falck JR, Reddy LM, Campbell WB. 14,15-EET analogs: characterization of structural requirements for agonist and antagonist activity in bovine coronary arteries. Pharmacol Res. 2004 Jun;49(6):515-24.
227. Carrier EJ, Kearn CS, Barkmeier AJ, Breese NM, Yang W, Nithipatikom K, Pfister SL, Campbell WB, Hillard CJ. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol Pharmacol. 2004 Apr;65(4):999-1007.
228. Pfister SL, Pratt PE, Kurian J, Campbell WB. Glibenclamide inhibits thromboxane-mediated vasoconstriction by thromboxane receptor blockade. Vascul Pharmacol. 2004 Jan;40(6):285-92.
229. Chen YF, Zhang AY, Zou AP, Campbell WB, Li PL. Protein methylation activates reconstituted ryanodine receptor-ca release channels from coronary artery myocytes. J Vasc Res. 2004 May-Jun;41(3):229-40.
230. Nithipatikom K, Holmes BB, McCoy MJ, Hillard CJ, Campbell WB. Chronic administration of nitric oxide reduces angiotensin II receptor type 1 expression and aldosterone synthesis in zona glomerulosa cells. Am J Physiol Endocrinol Metab. 2004 Nov;287(5):E820-7.
231. Zhang DX, Gauthier KM, Campbell WB. Acetylcholine-induced relaxation and hyperpolarization in small bovine adrenal cortical arteries: role of cytochrome P450 metabolites. Endocrinology. 2004 Oct;145(10):4532-9.
232. Falck JR, Barma DK, Mohapatra S, Bandyopadhyay A, Reddy KM, Qi J, Campbell WB. Asymmetric synthesis of the stereoisomers of 11,12,15(S)-trihydroxyeicosa-5(Z),8(Z),13(E)-trienoic acid, a potent endothelium-derived vasodilator. Bioorg Med Chem Lett. 2004 Oct 04;14(19):4987-90.
233. Nithipatikom K, Gross ER, Endsley MP, Moore JM, Isbell MA, Falck JR, Campbell WB, Gross GJ. Inhibition of cytochrome P450omega-hydroxylase: a novel endogenous cardioprotective pathway. Circ Res. 2004 Oct 15;95(8):e65-71.
234. Zhang DX, Gauthier KM, Chawengsub Y, Holmes BB, Campbell WB. Cyclooxygenase- and lipoxygenase-dependent relaxation to arachidonic acid in rabbit small mesenteric arteries. Am J Physiol Heart Circ Physiol. 2005 Jan;288(1):H302-9.
235. Zhang AY, Teggatz EG, Zou AP, Campbell WB, Li PL. Endostatin uncouples NO and Ca2+ response to bradykinin through enhanced O2*- production in the intact coronary endothelium. Am J Physiol Heart Circ Physiol. 2005 Feb;288(2):H686-94.
236. Gauthier KM, Baewer DV, Hittner S, Hillard CJ, Nithipatikom K, Reddy DS, Falck JR, Campbell WB. Endothelium-derived 2-arachidonylglycerol: an intermediate in vasodilatory eicosanoid release in bovine coronary arteries. Am J Physiol Heart Circ Physiol. 2005 Mar;288(3):H1344-51.
237. Gross ER, Nithipatikom K, Hsu AK, Peart JN, Falck JR, Campbell WB, Gross GJ. Cytochrome P450 omega-hydroxylase inhibition reduces infarct size during reperfusion via the sarcolemmal KATP channel. J Mol Cell Cardiol. 2004 Dec;37(6):1245-9.
238. Nithipatikom K, Endsley MP, Isbell MA, Falck JR, Iwamoto Y, Hillard CJ, Campbell WB. 2-arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Res. 2004 Dec 15;64(24):8826-30.
239. Nithipatikom K, Holmes BB, Isbell MA, Hanke CJ, Gomez-Sanchez CE, Campbell WB. Measurement of steroid synthesis in zona glomerulosa cells by liquid chromatography-electrospray ionization-mass spectrometry: inhibition by nitric oxide. Anal Biochem. 2005 Feb 15;337(2):203-10.
240. Gauthier KM, Edwards EM, Falck JR, Reddy DS, Campbell WB. 14,15-epoxyeicosatrienoic acid represents a transferable endothelium-dependent relaxing factor in bovine coronary arteries. Hypertension. 2005 Apr;45(4):666-71.
241. Yang W, Gauthier KM, Reddy LM, Sangras B, Sharma KK, Nithipatikom K, Falck JR, Campbell WB. Stable 5,6-epoxyeicosatrienoic acid analog relaxes coronary arteries through potassium channel activation. Hypertension. 2005 Apr;45(4):681-6.
242. Nithipatikom K, Isbell MA, See WA, Campbell WB. Elevated 12- and 20-hydroxyeicosatetraenoic acid in urine of patients with prostatic diseases. Cancer Lett. 2006 Feb 28;233(2):219-25.
243. Gauthier KM, Zhang DX, Edwards EM, Holmes B, Campbell WB. Angiotensin II dilates bovine adrenal cortical arterioles: role of endothelial nitric oxide. Endocrinology. 2005 Aug;146(8):3319-24.
244. Weston AH, Félétou M, Vanhoutte PM, Falck JR, Campbell WB, Edwards G. Bradykinin-induced, endothelium-dependent responses in porcine coronary arteries: involvement of potassium channel activation and epoxyeicosatrienoic acids. Br J Pharmacol. 2005 Jul;145(6):775-84. PMCID: PMC1576199
245. Charoenteeraboon J, Nithipatikom K, Campbell WB, Piyachaturawat P, Wilairat P, Rongnoparut P. Induction of human cholesterol 7alpha-hydroxylase in HepG2 cells by 2,4,6-trihydroxyacetophenone. Eur J Pharmacol. 2005 May 16;515(1-3):43-6.
246. Nithipatikom K, Endsley MP, Isbell MA, Wheelock CE, Hammock BD, Campbell WB. A new class of inhibitors of 2-arachidonoylglycerol hydrolysis and invasion of prostate cancer cells. Biochem Biophys Res Commun. 2005 Jul 15;332(4):1028-33. PMCID: PMC1450257
247. Tang X, Edwards EM, Holmes BB, Falck JR, Campbell WB. Role of phospholipase C and diacylglyceride lipase pathway in arachidonic acid release and acetylcholine-induced vascular relaxation in rabbit aorta. Am J Physiol Heart Circ Physiol. 2006 Jan;290(1):H37-45.
248. Zhang DX, Gauthier KM, Campbell WB. Mechanisms of histamine-induced relaxation in bovine small adrenal cortical arteries. Am J Physiol Endocrinol Metab. 2005 Dec;289(6):E1058-63.
249. Hatoum OA, Gauthier KM, Binion DG, Miura H, Telford G, Otterson MF, Campbell WB, Gutterman DD. Novel mechanism of vasodilation in inflammatory bowel disease. Arterioscler Thromb Vasc Biol. 2005 Nov;25(11):2355-61.
250. Campbell WB, Holmes BB, Falck JR, Capdevila JH, Gauthier KM. Regulation of potassium channels in coronary smooth muscle by adenoviral expression of cytochrome P-450 epoxygenase. Am J Physiol Heart Circ Physiol. 2006 Jan;290(1):H64-71.
251. Nithipatikom K, Endsley MP, Moore JM, Isbell MA, Falck JR, Campbell WB, Gross GJ. Effects of selective inhibition of cytochrome P-450 omega-hydroxylases and ischemic preconditioning in myocardial protection. Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H500-5.
252. Tang X, Holmes BB, Nithipatikom K, Hillard CJ, Kuhn H, Campbell WB. Reticulocyte 15-lipoxygenase-I is important in acetylcholine-induced endothelium-dependent vasorelaxation in rabbit aorta. Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):78-84.
253. Larsen BT, Miura H, Hatoum OA, Campbell WB, Hammock BD, Zeldin DC, Falck JR, Gutterman DD. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition. Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H491-9. PMCID: PMC1456013
254. McSherry IN, Sandow SL, Campbell WB, Falck JR, Hill MA, Dora KA. A role for heterocellular coupling and EETs in dilation of rat cremaster arteries. Microcirculation. 2006 Mar;13(2):119-30.
255. Wei S, Brittin JJ, Falck JR, Anjaiah S, Nithipatikom K, Cui L, Campbell WB, Capdevila JH. Chiral resolution of the epoxyeicosatrienoic acids, arachidonic acid epoxygenase metabolites. Anal Biochem. 2006 May 01;352(1):129-34.
256. Wang D, Chen S, Feng Y, Yang Q, Campbell BH, Tang X, Campbell WB. Reduced expression of 15-lipoxygenase 2 in human head and neck carcinomas. Tumour Biol. 2006;27(5):261-73.
257. Aggarwal NT, Holmes BB, Cui L, Viita H, Yla-Herttuala S, Campbell WB. Adenoviral expression of 15-lipoxygenase-1 in rabbit aortic endothelium: role in arachidonic acid-induced relaxation. Am J Physiol Heart Circ Physiol. 2007 Feb;292(2):H1033-41.
258. Hanke CJ, Holmes BB, Xu Y, Nithipatikom K, Campbell WB. Endothelium-derived steroidogenic factor enhances angiotensin II-stimulated aldosterone release by bovine zona glomerulosa cells. Endocrinology. 2007 Jan;148(1):317-23.
259. Larsen BT, Campbell WB, Gutterman DD. Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system. Trends Pharmacol Sci. 2007 Jan;28(1):32-8.
260. Campbell WB, Falck JR. Arachidonic acid metabolites as endothelium-derived hyperpolarizing factors. Hypertension. 2007 Mar;49(3):590-6.
261. Yi XY, Gauthier KM, Cui L, Nithipatikom K, Falck JR, Campbell WB. Metabolism of adrenic acid to vasodilatory 1alpha,1beta-dihomo-epoxyeicosatrienoic acids by bovine coronary arteries. Am J Physiol Heart Circ Physiol. 2007 May;292(5):H2265-74.
262. Falck JR, Reddy LM, Byun K, Campbell WB, Yi XY. Epoxygenase eicosanoids: synthesis of tetrahydrofuran-diol metabolites and their vasoactivity. Bioorg Med Chem Lett. 2007 May 01;17(9):2634-8. PMCID: PMC1950572
263. Yang W, Holmes BB, Gopal VR, Kishore RV, Sangras B, Yi XY, Falck JR, Campbell WB. Characterization of 14,15-epoxyeicosatrienoyl-sulfonamides as 14,15-epoxyeicosatrienoic acid agonists: use for studies of metabolism and ligand binding. J Pharmacol Exp Ther. 2007 Jun;321(3):1023-31.
264. Zhang DX, Gauthier KM, Chawengsub Y, Campbell WB. ACh-induced relaxations of rabbit small mesenteric arteries: role of arachidonic acid metabolites and K+. Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H152-9.
265. Endsley MP, Aggarwal N, Isbell MA, Wheelock CE, Hammock BD, Falck JR, Campbell WB, Nithipatikom K. Diverse roles of 2-arachidonoylglycerol in invasion of prostate carcinoma cells: Location, hydrolysis and 12-lipoxygenase metabolism. Int J Cancer. 2007 Sep 01;121(5):984-91. PMCID: PMC2565646
266. Zhang DX, Gauthier KM, Falck JR, Siddam A, Campbell WB. Steroid-producing cells regulate arterial tone of adrenal cortical arteries. Endocrinology. 2007 Aug;148(8):3569-76.
267. Cui L, Nithipatikom K, Campbell WB. Simultaneous analysis of angiotensin peptides by LC-MS and LC-MS/MS: metabolism by bovine adrenal endothelial cells. Anal Biochem. 2007 Oct 01;369(1):27-33. PMCID: PMC2754136
268. Hillard CJ, Shi L, Tuniki VR, Falck JR, Campbell WB. Studies of anandamide accumulation inhibitors in cerebellar granule neurons: comparison to inhibition of fatty acid amide hydrolase. J Mol Neurosci. 2007 Sep;33(1):18-24. PMCID: PMC2248273
269. Larsen BT, Gutterman DD, Sato A, Toyama K, Campbell WB, Zeldin DC, Manthati VL, Falck JR, Miura H. Hydrogen peroxide inhibits cytochrome p450 epoxygenases: interaction between two endothelium-derived hyperpolarizing factors. Circ Res. 2008 Jan 04;102(1):59-67. PMCID: PMC2364729
270. Tang X, Aggarwal N, Holmes BB, Kuhn H, Campbell WB. Age-related decrease in 15-lipoxygenase contributes to reduced vasorelaxation in rabbit aorta. Am J Physiol Heart Circ Physiol. 2008 Feb;294(2):H679-87.
271. Gauthier KM, Yang W, Gross GJ, Campbell WB. Roles of epoxyeicosatrienoic acids in vascular regulation and cardiac preconditioning. J Cardiovasc Pharmacol. 2007 Dec;50(6):601-8.
272. Yang W, Tuniki VR, Anjaiah S, Falck JR, Hillard CJ, Campbell WB. Characterization of epoxyeicosatrienoic acid binding site in U937 membranes using a novel radiolabeled agonist, 20-125i-14,15-epoxyeicosa-8(Z)-enoic acid. J Pharmacol Exp Ther. 2008 Mar;324(3):1019-27.
273. Aggarwal NT, Chawengsub Y, Gauthier KM, Viita H, Yla-Herttuala S, Campbell WB. Endothelial 15-lipoxygenase-1 overexpression increases acetylcholine-induced hypotension and vasorelaxation in rabbits. Hypertension. 2008 Feb;51(2):246-51.
274. Chawengsub Y, Aggarwal NT, Nithipatikom K, Gauthier KM, Anjaiah S, Hammock BD, Falck JR, Campbell WB. Identification of 15-hydroxy-11,12-epoxyeicosatrienoic acid as a vasoactive 15-lipoxygenase metabolite in rabbit aorta. Am J Physiol Heart Circ Physiol. 2008 Mar;294(3):H1348-56.
275. Gauthier KM, Chawengsub Y, Goldman DH, Conrow RE, Anjaiah S, Falck JR, Campbell WB. 11(R),12(S),15(S)-trihydroxyeicosa-5(Z),8(Z),13(E)-trienoic acid: an endothelium-derived 15-lipoxygenase metabolite that relaxes rabbit aorta. Am J Physiol Heart Circ Physiol. 2008 Mar;294(3):H1467-72.
276. Cui L, Isbell MA, Chawengsub Y, Falck JR, Campbell WB, Nithipatikom K. Structural characterization of monohydroxyeicosatetraenoic acids and dihydroxy- and trihydroxyeicosatrienoic acids by ESI-FTICR. J Am Soc Mass Spectrom. 2008 Apr;19(4):569-85. PMCID: PMC2373256
277. Thill R, Campbell WB, Williams CL. Identification and characterization of the unique guanine nucleotide exchange factor, SmgGDS, in vascular smooth muscle cells. J Cell Biochem. 2008 Aug 01;104(5):1760-70.
278. Gross GJ, Gauthier KM, Moore J, Falck JR, Hammock BD, Campbell WB, Nithipatikom K. Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. Am J Physiol Heart Circ Physiol. 2008 Jun;294(6):H2838-44. PMCID: PMC2863006
279. Aggarwal NT, Gauthier KM, Campbell WB. 15-Lipoxygenase metabolites contribute to age-related reduction in acetylcholine-induced hypotension in rabbits. Am J Physiol Heart Circ Physiol. 2008 Jul;295(1):H89-96. PMCID: PMC2494760
280. Gauthier KM, Zhang DX, Cui L, Nithipatikom K, Campbell WB. Angiotensin II relaxations of bovine adrenal cortical arteries: role of angiotensin II metabolites and endothelial nitric oxide. Hypertension. 2008 Jul;52(1):150-5. PMCID: PMC3202425
281. Endsley MP, Thill R, Choudhry I, Williams CL, Kajdacsy-Balla A, Campbell WB, Nithipatikom K. Expression and function of fatty acid amide hydrolase in prostate cancer. Int J Cancer. 2008 Sep 15;123(6):1318-26. PMCID: PMC2548421
282. Nithipatikom K, Campbell WB. Roles of Eicosanoids in Prostate Cancer. Future Lipidol. 2008 Aug 01;3(4):453-467. PMCID: PMC3928987
283. Aggarwal NT, Pfister SL, Campbell WB. Hypercholesterolemia enhances 15-lipoxygenase-mediated vasorelaxation and acetylcholine-induced hypotension. Arterioscler Thromb Vasc Biol. 2008 Dec;28(12):2209-15.
284. Aggarwal NT, Pfister SL, Gauthier KM, Chawengsub Y, Baker JE, Campbell WB. Chronic hypoxia enhances 15-lipoxygenase-mediated vasorelaxation in rabbit arteries. Am J Physiol Heart Circ Physiol. 2009 Mar;296(3):H678-88. PMCID: PMC2660232
285. Gross GJ, Gauthier KM, Moore J, Campbell WB, Falck JR, Nithipatikom K. Evidence for role of epoxyeicosatrienoic acids in mediating ischemic preconditioning and postconditioning in dog. Am J Physiol Heart Circ Physiol. 2009 Jul;297(1):H47-52. PMCID: PMC2711741
286. Chawengsub Y, Gauthier KM, Campbell WB. Role of arachidonic acid lipoxygenase metabolites in the regulation of vascular tone. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H495-507. PMCID: PMC2724209
287. Falck JR, Kodela R, Manne R, Atcha KR, Puli N, Dubasi N, Manthati VL, Capdevila JH, Yi XY, Goldman DH, Morisseau C, Hammock BD, Campbell WB. 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition. J Med Chem. 2009 Aug 27;52(16):5069-75. PMCID: PMC2888647
288. Chawengsub Y, Gauthier KM, Nithipatikom K, Hammock BD, Falck JR, Narsimhaswamy D, Campbell WB. Identification of 13-hydroxy-14,15-epoxyeicosatrienoic acid as an acid-stable endothelium-derived hyperpolarizing factor in rabbit arteries. J Biol Chem. 2009 Nov 06;284(45):31280-90. PMCID: PMC2781526
289. Chen Y, Falck JR, Tuniki VR, Campbell WB. 20-125Iodo-14,15-epoxyeicosa-5(Z)-enoic acid: a high-affinity radioligand used to characterize the epoxyeicosatrienoic acid antagonist binding site. J Pharmacol Exp Ther. 2009 Dec;331(3):1137-45. PMCID: PMC2784706
290. Kopf PG, Zhang DX, Gauthier KM, Nithipatikom K, Yi XY, Falck JR, Campbell WB. Adrenic acid metabolites as endogenous endothelium-derived and zona glomerulosa-derived hyperpolarizing factors. Hypertension. 2010 Feb;55(2):547-54. PMCID: PMC2819927
291. Campbell WB, Fleming I. Epoxyeicosatrienoic acids and endothelium-dependent responses. Pflugers Arch. 2010 May;459(6):881-95. PMCID: PMC3373596
292. Yaghini FA, Song CY, Lavrentyev EN, Ghafoor HU, Fang XR, Estes AM, Campbell WB, Malik KU. Angiotensin II-induced vascular smooth muscle cell migration and growth are mediated by cytochrome P450 1B1-dependent superoxide generation. Hypertension. 2010 Jun;55(6):1461-7. PMCID: PMC2916227
293. Nithipatikom K, Brody DM, Tang AT, Manthati VL, Falck JR, Williams CL, Campbell WB. Inhibition of carcinoma cell motility by epoxyeicosatrienoic acid (EET) antagonists. Cancer Sci. 2010 Dec;101(12):2629-36. PMCID: PMC3398840
294. Bukhari IA, Gauthier KM, Jagadeesh SG, Sangras B, Falck JR, Campbell WB. 14,15-Dihydroxy-eicosa-5(Z)-enoic acid selectively inhibits 14,15-epoxyeicosatrienoic acid-induced relaxations in bovine coronary arteries. J Pharmacol Exp Ther. 2011 Jan;336(1):47-55. PMCID: PMC3014297
295. Pfister SL, Gauthier KM, Campbell WB. Vascular pharmacology of epoxyeicosatrienoic acids. Adv Pharmacol. 2010;60:27-59. PMCID: PMC3373307
296. Nithipatikom K, Isbell MA, Endsley MP, Woodliff JE, Campbell WB. Anti-proliferative effect of a putative endocannabinoid, 2-arachidonylglyceryl ether in prostate carcinoma cells. Prostaglandins Other Lipid Mediat. 2011 Feb;94(1-2):34-43. PMCID: PMC3039283
297. Kopf PG, Gauthier KM, Zhang DX, Falck JR, Campbell WB. Angiotensin II regulates adrenal vascular tone through zona glomerulosa cell-derived EETs and DHETs. Hypertension. 2011 Feb;57(2):323-9. PMCID: PMC3034648
298. Gauthier KM, Goldman DH, Aggarwal NT, Chawengsub Y, Falck JR, Campbell WB. Role of arachidonic acid lipoxygenase metabolites in acetylcholine-induced relaxations of mouse arteries. Am J Physiol Heart Circ Physiol. 2011 Mar;300(3):H725-35. PMCID: PMC3064304
299. Pfister SL, Nithipatikom K, Campbell WB. Role of superoxide and thromboxane receptors in acute angiotensin II-induced vasoconstriction of rabbit vessels. Am J Physiol Heart Circ Physiol. 2011 Jun;300(6):H2064-71. PMCID: PMC3119100
300. Chen Y, Falck JR, Manthati VL, Jat JL, Campbell WB. 20-Iodo-14,15-epoxyeicosa-8(Z)-enoyl-3-azidophenylsulfonamide: photoaffinity labeling of a 14,15-epoxyeicosatrienoic acid receptor. Biochemistry. 2011 May 10;50(18):3840-8. PMCID: PMC3100183
301. Gauthier KM, Olson L, Harder A, Isbell M, Imig JD, Gutterman DD, Falck JR, Campbell WB. Soluble epoxide hydrolase contamination of specific catalase preparations inhibits epoxyeicosatrienoic acid vasodilation of rat renal arterioles. Am J Physiol Renal Physiol. 2011 Oct;301(4):F765-72. PMCID: PMC3191800
302. Spector AA, Campbell WB, Zeldin DC. Eicosanoids and disease. Introduction. Prostaglandins Other Lipid Mediat. 2011 Nov;96(1-4):1-2.
303. Nithipatikom K, Gomez-Granados AD, Tang AT, Pfeiffer AW, Williams CL, Campbell WB. Cannabinoid receptor type 1 (CB1) activation inhibits small GTPase RhoA activity and regulates motility of prostate carcinoma cells. Endocrinology. 2012 Jan;153(1):29-41. PMCID: PMC3249681
304. Jennings BL, Anderson LJ, Estes AM, Fang XR, Song CY, Campbell WB, Malik KU. Involvement of cytochrome P-450 1B1 in renal dysfunction, injury, and inflammation associated with angiotensin II-induced hypertension in rats. Am J Physiol Renal Physiol. 2012 Feb 15;302(4):F408-20. PMCID: PMC3289420
305. Jennings BL, Anderson LJ, Estes AM, Yaghini FA, Fang XR, Porter J, Gonzalez FJ, Campbell WB, Malik KU. Cytochrome P450 1B1 contributes to renal dysfunction and damage caused by angiotensin II in mice. Hypertension. 2012 Feb;59(2):348-54. PMCID: PMC3268066
306. Aggarwal NT, Gauthier KM, Campbell WB. Endothelial nitric oxide and 15-lipoxygenase-1 metabolites independently mediate relaxation of the rabbit aorta. Vascul Pharmacol. 2012 Jan-Feb;56(1-2):106-12. PMCID: PMC3268834
307. Bukhari IA, Shah AJ, Gauthier KM, Walsh KA, Koduru SR, Imig JD, Falck JR, Campbell WB. 11,12,20-Trihydroxy-eicosa-8(Z)-enoic acid: a selective inhibitor of 11,12-EET-induced relaxations of bovine coronary and rat mesenteric arteries. Am J Physiol Heart Circ Physiol. 2012 Apr 15;302(8):H1574-83. PMCID: PMC3330801
308. Tang AT, Campbell WB, Nithipatikom K. ROCK1 feedback regulation of the upstream small GTPase RhoA. Cell Signal. 2012 Jul;24(7):1375-80. PMCID: PMC3335987
309. Kriska T, Cepura C, Magier D, Siangjong L, Gauthier KM, Campbell WB. Mice lacking macrophage 12/15-lipoxygenase are resistant to experimental hypertension. Am J Physiol Heart Circ Physiol. 2012 Jun 01;302(11):H2428-38. PMCID: PMC3378305
310. Jennings BL, Estes AM, Anderson LJ, Fang XR, Yaghini FA, Fan Z, Gonzalez FJ, Campbell WB, Malik KU. Cytochrome P450 1B1 gene disruption minimizes deoxycorticosterone acetate-salt-induced hypertension and associated cardiac dysfunction and renal damage in mice. Hypertension. 2012 Dec;60(6):1510-6. PMCID: PMC3499668
311. Siangjong L, Gauthier KM, Pfister SL, Smyth EM, Campbell WB. Endothelial 12(S)-HETE vasorelaxation is mediated by thromboxane receptor inhibition in mouse mesenteric arteries. Am J Physiol Heart Circ Physiol. 2013 Feb 01;304(3):H382-92. PMCID: PMC3774504
312. Oki K, Kopf PG, Campbell WB, Luis Lam M, Yamazaki T, Gomez-Sanchez CE, Gomez-Sanchez EP. Angiotensin II and III metabolism and effects on steroid production in the HAC15 human adrenocortical cell line. Endocrinology. 2013 Jan;154(1):214-21. PMCID: PMC3529373
313. Campbell WB, Gauthier KM. Inducible endothelium-derived hyperpolarizing factor: role of the 15-lipoxygenase-EDHF pathway. J Cardiovasc Pharmacol. 2013 Mar;61(3):176-87. PMCID: PMC3594564
314. Ohta M, Toyama K, Gutterman DD, Campbell WB, Lemaître V, Teraoka R, Miura H. Ecto-5'-nucleotidase, CD73, is an endothelium-derived hyperpolarizing factor synthase. Arterioscler Thromb Vasc Biol. 2013 Mar;33(3):629-36. PMCID: PMC3587694
315. Zheng X, Zinkevich NS, Gebremedhin D, Gauthier KM, Nishijima Y, Fang J, Wilcox DA, Campbell WB, Gutterman DD, Zhang DX. Arachidonic acid-induced dilation in human coronary arterioles: convergence of signaling mechanisms on endothelial TRPV4-mediated Ca2+ entry. J Am Heart Assoc. 2013 Apr 25;2(3):e000080. PMCID: PMC3698766
316. Gauthier KM, Cepura CJ, Campbell WB. ACE inhibition enhances bradykinin relaxations through nitric oxide and B1 receptor activation in bovine coronary arteries. Biol Chem. 2013 Sep;394(9):1205-12. PMCID: PMC3979287
317. Kriska T, Cepura C, Siangjong L, Wan TC, Auchampach JA, Shaish A, Haratz D, Kumar G, Falck JR, Gauthier KM, Campbell WB. Effect of human 15-lipoxygenase-1 metabolites on vascular function in mouse mesenteric arteries and hearts. Prostaglandins Other Lipid Mediat. 2013 Oct;106:8-15. PMCID: PMC3844054
318. Kopf PG, Campbell WB. Endothelial metabolism of angiotensin II to angiotensin III, not angiotensin (1-7), augments the vasorelaxation response in adrenal cortical arteries. Endocrinology. 2013 Dec;154(12):4768-76. PMCID: PMC3836075
319. Kriska T, Cepura C, Gauthier KM, Campbell WB. Role of macrophage PPARγ in experimental hypertension. Am J Physiol Heart Circ Physiol. 2014 Jan 01;306(1):H26-32. PMCID: PMC3920151
320. Ansurudeen I, Kopf PG, Gauthier KM, Bornstein SR, Cowley AW Jr, Campbell WB. Aldosterone secretagogues increase adrenal blood flow in male rats. Endocrinology. 2014 Jan;155(1):127-32. PMCID: PMC3868807
321. Hye Khan MA, Pavlov TS, Christain SV, Neckář J, Staruschenko A, Gauthier KM, Capdevila JH, Falck JR, Campbell WB, Imig JD. Epoxyeicosatrienoic acid analogue lowers blood pressure through vasodilation and sodium channel inhibition. Clin Sci (Lond). 2014 Oct;127(7):463-74. PMCID: PMC4167712
322. Gauthier KM, Campbell WB, McNeish AJ. Regulation of KCa2.3 and endothelium-dependent hyperpolarization (EDH) in the rat middle cerebral artery: the role of lipoxygenase metabolites and isoprostanes. PeerJ. 2014;2:e414. PMCID: PMC4060036
323. Nithipatikom K, Endsley MP, Pfeiffer AW, Falck JR, Campbell WB. A novel activity of microsomal epoxide hydrolase: metabolism of the endocannabinoid 2-arachidonoylglycerol. J Lipid Res. 2014 Oct;55(10):2093-102. PMCID: PMC4174002
324. Falck JR, Koduru SR, Mohapatra S, Manne R, Atcha KR, Atcha R, Manthati VL, Capdevila JH, Christian S, Imig JD, Campbell WB. 14,15-Epoxyeicosa-5,8,11-trienoic Acid (14,15-EET) surrogates: carboxylate modifications. J Med Chem. 2014 Aug 28;57(16):6965-72. PMCID: PMC4148164
325. Khan AH, Falck JR, Manthati VL, Campbell WB, Imig JD. Epoxyeicosatrienoic acid analog attenuates angiotensin II hypertension and kidney injury. Front Pharmacol. 2014;5:216. PMCID: PMC4172029
326. Shah AJ, Gauthier KM, Imig JD, Falck JR, Campbell WB. WX-III-287-19 A Possible Thromboxane Antagonist in Bovine Coronary Arteries. Value Health. 2014 Nov;17(7):A732-3.
327. Siangjong L, Goldman DH, Kriska T, Gauthier KM, Smyth EM, Puli N, Kumar G, Falck JR, Campbell WB. Vascular hepoxilin and trioxilins mediate vasorelaxation through TP receptor inhibition in mouse arteries. Acta Physiol (Oxf). 2017 01;219(1):188-201. PMCID: PMC4909587
328. Campbell WB, Imig JD, Schmitz JM, Falck JR. Orally Active Epoxyeicosatrienoic Acid Analogs. J Cardiovasc Pharmacol. 2017 Oct;70(4):211-224. PMCID: PMC5673125
329. Kopf PG, Park SK, Herrnreiter A, Krause C, Roques BP, Campbell WB. Obligatory Metabolism of Angiotensin II to Angiotensin III for Zona Glomerulosa Cell-Mediated Relaxations of Bovine Adrenal Cortical Arteries. Endocrinology. 2018 01 01;159(1):238-247. PMCID: PMC5761603
330. Shah AJ, Kriska T, Gauthier KM, Falck JR, Campbell WB. Effect of Angiotensin II and ACTH on Adrenal Blood Flow in the Male Rat Adrenal Gland In Vivo. Endocrinology. 2018 01 01;159(1):217-226. PMCID: PMC5761607
331. Kriska T, Thomas MJ, Falck JR, Campbell WB. Deactivation of 12(S)-HETE through (ω-1)-hydroxylation and β-oxidation in alternatively activated macrophages. J Lipid Res. 2018 04;59(4):615-624. PMCID: PMC5880500
332. Park SK, Herrnreiter A, Pfister SL, Gauthier KM, Falck BA, Falck JR, Campbell WB. GPR40 is a low-affinity epoxyeicosatrienoic acid receptor in vascular cells. J Biol Chem. 2018 07 06;293(27):10675-10691. PMCID: PMC6036206
333. Neckář J, Hye Khan MA, Gross GJ, Cyprová M, Hrdlička J, Kvasilová A, Falck JR, Campbell WB, Sedláková L, Škutová Š, Olejníčková V, Gregorovičová M, Sedmera D, Kolář F, Imig JD. Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats. Clin Sci (Lond). 2019 Apr 30;133(8):939-951. PMCID: PMC6492034
334. Falck JR, Koduru SR, Mohapatra S, Manne R, Atcha KR, Manthati VL, Capdevila JH, Christian S, Imig JD, Campbell WB. Erratum: 14,15-epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates: Carboxylate modifications (Journal of Medicinal Chemistry (2014) 57 (6965-6972) DOI: 10.1021/jm500262m) Journal of Medicinal Chemistry. 13 November 2014;57(21):9218.
335. Gebremedhin D, Lange AR, Campbell WB, Hillard CJ, Harder DR. Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca<sup>2+</sup> channel current American Journal of Physiology. 1999;276(6 PART 2).
336. Nithipatikom K, McCoy MJ, Kajdacsy-Balla A, Kaul S, Lindholm PF, Hawi SR, Rochanakij S, Adar F, Campbell WB. Detection of prostaglandin H synthase (cyclooxygenase)-1 and -2 expression in single cancer cells by confocal Raman microspectroscopy Proceedings of SPIE - The International Society for Optical Engineering. 1999;3608:20-27.
337. McCoy MJ, Habermann TJ, Hanke CJ, Adar F, Campbell WB, Nithipatikom K. Detection of angiotensin II binding to single adrenal zona glomerulosa cells by confocal Raman microspectroscopy Proceedings of SPIE - The International Society for Optical Engineering. 1999;3608:195-203.
338. Pin-Lan LI, Zou AIP, Campbell WB. Regulation of K<inf>ca</inf>-channel activity by cyclic ADP-ribose and ADP-ribose in coronary arterial smooth muscle American Journal of Physiology. 1998;275(3 PART 2).
339. Falck JR, Chauhan K, Rosolowsky M, Campbell WB. Vasoactive eicosanoids: Synthesis of 12,20-dihydroxyeicosa-5(Z),8(Z),10(E),14(Z)-tetraenoic acid via a novel chiral bis-lactol Bioorganic and Medicinal Chemistry Letters. 8 September 1994;4(17):2113-2116.
340. Ashton JH, Schmitz JM, Campbell WB, Ogletree ML, Raheja S, Taylor AL, Fitzgerald C, Buja LM, Willerson JT. Inhibition of cyclic flow variations in stenosed canine coronary arteries by thromboxane A <inf>2</inf> /prostaglandin H <inf>2</inf> receptor antagonists Circulation Research. 1986;59(5):568-578.
341. Ashton JH, Benedict CR, Fitzgerald C, Raheja S, Taylor A, Campbell WB, Buja LM, Willerson JT. Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries Circulation. 1986;73(3):572-578.
342. Schmitz JM, Apprill PG, Buja LM, Willerson JT, Campbell WB. Vascular prostaglandin and thromboxane production in a canine model of myocardial ischemia Circulation Research. 1985;57(2):223-231.
343. Apprill P, Schmitz JM, Campbell WB, Tilton G, Ashton J, Raheja S, Buja LM, Willerson JT. Cyclic blood flow variations induced by platelet-activating factor in stenosed canine coronary arteries despite inhibition of thromboxane synthetase, serotonin receptors, and α-adrenergic receptors Circulation. 1985;72(2):397-405.
344. Winniford MD, Jackson J, Malloy CR, Rehr RB, Campbell WB, David Hillis L. Does indomethacin attenuate the coronary vasodilatory effect of nitroglycerin? Journal of the American College of Cardiology. 1984;4(6):1114-1117.
345. Nicod P, Rehr R, Winniford MD, Campbell WB, Firth BG, David Hillis L. Acute systemic and coronary hemodynamic and serologic responses to cigarette smoking in long-term smokers with atherosclerotic coronary artery disease Journal of the American College of Cardiology. 1984;4(5):964-971.
346. Bush LR, Campbell WB, Buja LM, Tilton GD, Willerson JT. Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries Circulation. 1984;69(6):1161-1170.
347. Kaojarern S, Chennavasin P, Burdette A, Campbell WB, Brater DC. Dependence of urinary prostaglandin E<inf>2</inf> excretion on urinary volume rather than solute handling or segmental nephron function in man Clinical Science. 1984;67(4):413-420.
348. Bush LR, Campbell WB, Kern K, Tilton GD, Apprill P, Ashton J, Schmitz J, Buja LM, Willerson JT. The effects of α<inf>2</inf>-adrenergic and serotonergic receptor antagonists on cyclic blood flow alterations in stenosed canine coronary arteries Circulation Research. 1984;55(5):642-652.
349. Henrich WL, Hamasaki Y, Said SI, Campbell WB, Cronin RE. Dissociation of systemic and renal effects in endotoxemia. Prostaglandin inhibition uncovers an important role of renal nerves Journal of Clinical Investigation. 1982;69(3):691-699.
350. . Thromboxane in ischemic heart disease. N Engl J Med. 1981 Jul 09;305(2):106-7.
351. Levin DL, Mills LJ, Parkey M, Garriott J, Campbell W. Constriction of the fetal ductus arteriosus after administration of indomethacin to the pregnant ewe. J Pediatr. 1979 Apr;94(4):647-50.
352. Jackson EK, Campbell WB. Inhibition of neuronal noradrenaline uptake by angiotensin II in the rat mesentery Canadian Journal of Physiology and Pharmacology. 1979;57(12):1443-1447.
353. Sampson D, LaPorta AJ, Kauffman HM, Campbell WB. Plasma aldosterone levels after renal transplantation IRCS Medical Science: Biochemistry. 1976;4(10):462.
 
Books, Chapters, and Reviews
1. Pettinger WA and Campbell WB: The rat as a model for the study of the renin-angiotensin-aldosterone-sodium (RAAS) axis. IN: New Antihypertensive Drugs (Scriabine A and Sweet C, eds.), Spectrum Publications, New York, 1976, pp. 179-192.
2. Hirsh PD, Hillis LD, Campbell WB, Firth BG and Willerson JT: Coronary prostacyclin and thromboxane levels in patients with coronary artery disease. IN: Prostaglandins in Clinical Medicine: Cardiovascular and Thrombotic Disorders. (Wu KK and Rossi EC, eds.) Year Book Medical Publishers, Chicago, IL 1982, pp. 273-287.
3. Hillis LD, Hirsh PD, Campbell WB and Firth BG: Interactions of the arterial wall, plaque, and platelets in myocardial ischemia and infarction. IN: Coronary Artery Spasm and Thrombosis, Cardiovascular Clinics. (Goldberg S, ed.) F.A. Davis Company, Philadelphia, PA 1983, pp. 31-44.
4. Pettinger WA and Campbell WB: Renin. IN: Textbook of Nephrology. (Massry SG and Glassock RJ, eds.) Williams and Wilkins, Baltimore, MD, 1983, 2.30-2.33.
5. Keeton TK and Campbell WB: The control of renin release and its alteration by drugs. IN: Cardiovascular Pharmacology, 2nd Ed. (Antonaccio MJ, ed.) Raven Press, New York 1984, pp. 65-118.
6. Johnson AR, Revtyak GE, Ibe BO and Campbell WB: Endothelial cells metabolize but do not synthesize leukotrienes. IN: Leukotrienes in Cardiovascular and Pulmonary Function. Alan R. Liss, Inc. 1985, pp. 185-196.
7. Campbell WB and Ojeda SR: Measurement of prostaglandins by radioimmunoassay. IN: Methods in Enzymology: Cellular Regulators, Part B Calcium and Lipids (Conn PM and Means AR, eds.) Academic Press, Inc., 1987, 141:323-340.
8. Campbell WB: Adrenal Steroids. IN: Goth's Medical Pharmacology, 12th Ed. (Clark WG, Brater DC and Johnson AR, eds.) C.V. Mosby, St. Louis, 1988, pp. 543-556.
9. Campbell WB: Lipid-derived autocoids: Eicosanoids and platelet-activating factor. IN: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed. (Gilman AG, Rall TW, Nies AJ and Taylor P, eds.) Pergamon Press, New York, 1990, pp. 600-617.
10. Campbell WB: Adrenal Steroids. IN: Goth's Medical Pharmacology, 13th ed. (Clark WG, Brater DC and Johnson AC, eds.) C.V. Mosby, St. Louis, 1990, pp. 527-540.
11. Campbell WB: Prostaglandins and Leukotrienes IN: Goth's Medical Pharmacology, 9th ed. (Clark WG, Brater DC and Johnson AC, eds.) C.V. Mosby, St. Louis, 1992, pp. 220-230.
12. Campbell WB and Halushka PV: Lipid-derived autocoids: Eicosanoids and platelet-activating factor. IN: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed. (Gilman AG, Rall TW, Nies AJ and Taylor P, eds.) Pergamon Press, New York, 1996, pp. 601-616.
13. Harder DR, Campbell WB, Gebremedhin D and Pratt PF: Bioassay of a cytochrome P450-dependent endothelial-derived hyperpolarizing factor from bovine coronary arteries. IN: Endothelium-Derived Hyperpolarizing Factor, (Vanhoutte PM, ed.) Harwood Academic Publishers, Volume One, 1996, pp. 73-80.
14. Campbell WB, Pratt PF, Gebremedhin D, and Harder D: Epoxyeicosatrienoic acids are endothelium-derived hyperpolarizing vasodilating factors in bovine coronary arteries. IN: Endothelium-Derived Hyperpolarizing Factor, (Vanhoutte PM, ed.) Harwood Academic Publishers, Volume One, 1996, pp. 81-89.
15. Li P-L, Zou A-P and Campbell WB: Metabolism and actions of ADP-riboses in coronary arterial smooth muscle. IN: ADP-Ribosylation in Animal Tissue (Haag and Koch-Nolte, eds.) Plenum Press, New York, 1997, pp. 437-441.
16. Campbell WB: Eicosanoids. IN: 9th Edition of the McGraw Hill Encyclopedia of Science and Technology.
17. Campbell WB, Zou A-P and Li P-L: Epoxyeicosatrienoic acids as endothelium-derived hyperpolarization factors in coronary arteries: Potassium channel activation through endogenous ADP-ribosylation of Gs. IN: Endothelium-Derived Hyperpolarizations (Vanhoutte PM, ed.), Harwood Academic Publishers, 1999, pp. 11-16.
18. Pfister SL, Spitzbarth N, Nithipatikom K, Edgemond WE and Campbell WB: Endothelium-derived eicosanoids from lipoxygenase relax rabbit aorta via potassium channel activation. IN: Endothelium-Derived Hyperpolarizations (Vanhoutte PM, ed.), Harwood Academic Publishers, 1999, pp. 17-28.
19. Pfister SL, Spitzbarth N, Gauthier KM and Campbell WB: Identification of 11,12,15-trihydroxyeicosatrienoic acid as the mediator of acetylcholine- and arachidonic acid-induced relaxations in rabbit aorta. IN: EDHF 2000, (Vanhoutte PM, ed.), Taylor and Francis Inc, 2001, pp. 239-248.
20. Harder DR, Zhang CC, Taheri MR, Narayanan J, Roman RJ, Voskuil CE, Campbell WB and Medhora M: Cytochrome P450 isoforms in the brain encode cell specific hyperpolarizing factors with a common mechanism of action. IN: EDHF 2000, (Vanhoutte PM, ed.), Taylor and Francis Inc, 2001, pp. 222-227.
21. Li P-L, Zou A-P and Campbell WB: Cyclic ADP-ribose, Ca2+ signaling and vascular tone, IN: Cyclic ADP-Ribose and NAADP, structures, metabolism and functions. (Hon Cheung Lee, ed.), Chapter 11, 2002, pp. 145-160.
22. Li P-L, Zou A-P and Campbell WB: Cyclic ADP-ribose and vasomotor response, IN: Cyclic ADP-Ribose and NAADP, structures, metabolism and functions. (Hon Cheung Lee, ed.), Chapter 16, 2002, pp. 343-363.
23. Gauthier KM, Pratt PF, Falck JR, and Campbell WB: Inhibition of bradykinin-induced relaxations by an epoxyeicosatrienoic acid antagonist: 14,15-epoxyeicosa-5Z-monoenoic acid IN: EDHF 2002, (Vanhoutte PM, ed.), Taylor and Francis Inc, Chapter 41, 2002, pp. 325-331.
24. Gauthier KM, Yang W, Gross GJ and Campbell WB. Roles of epoxyeicosatrienoic acids in vascular regulation and cardiac preconditioning. J Cardiovasc Pharmacolol. 50:601-608, 2007.
25. Pfister SL, Gauthier KM and Campbell WB: Vascular pharmacology of epoxyeicosatrienoic acids. Advances in Pharmacology. Submitted 2010.
 

jenkins-FCD Prod-410 e9586552fe7f53c71f7923aa6e27aeabbd3c2473